EurekaMag Full Text Articles Chapter 12,409

Sissung, T.M.; Price, D.K.; Sparreboom, A.; Figg, W.D. 2006: Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Molecular Cancer Research: Mcr 4(3): 135-150

Koo, S.Hwee.; Lee, E.Jon.Deoon. 2006: Pharmacogenetics approach to therapeutics. Clinical and Experimental Pharmacology and Physiology 33(5-6): 525-532

Hindorf, U.; Lindqvist, M.; Peterson, C.; Söderkvist, P.; Ström, M.; Hjortswang, H.; Pousette, A.; Almer, S. 2006: Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55(10): 1423-1431

Donnelly, J.G. 2004: Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Therapeutic Drug Monitoring 26(2): 231-235

McCarthy, A.D.; Kennedy, J.L.; Middleton, L.T. 2005: Pharmacogenetics in drug development. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 360(1460): 1579-1588

Hall, S., T.; Abbott, N.; Schmith, G.; Brazell, C. 2004: Pharmacogenetics in drug development: Regulatory and clinical considerations. Drug Development Research 62(2): 102-111

Shah, R.R. 2005: Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 360(1460): 1617-1638

Stöhlmacher, J. 2005: Pharmacogenetics in gastrointestinal tumors. Onkologie 28(8-9): 435-440

Williams, R.S.B. 2005: Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29(6): 1029-1037

Anglicheau, D.; Legendre, C.; Thervet, E. 2004: Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78(3): 311-315

Cronstein, B.N. 2004: Pharmacogenetics in the rheumatic diseases. Annals of the Rheumatic Diseases 63(Suppl): Ii25-Ii27

Kajinami, K.; Takekoshi, N.; Brousseau, M.E.; Schaefer, E.J. 2004: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177(2): 219-234

Morin, S.; Bodin, L.; Loriot, M.-A.; Thijssen, H.H.W.; Robert, A.; Strabach, S.; Verstuyft, C.él.; Tregouet, D.-A.; Dubert, L.; Laurent-Puig, P.; Funck-Brentano, C.; Jaillon, P.; Beaune, P.H.; Becquemont, L. 2004: Pharmacogenetics of acenocoumarol pharmacodynamics. Clinical Pharmacology and Therapeutics 75(5): 403-414

Palmer, S.N.; Giesecke, N.Martin.; Body, S.C.; Shernan, S.K.; Fox, A.A.; Collard, C.D. 2005: Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 102(3): 663-671

Giovannetti, E.; Mey, V.; Nannizzi, S.; Pasqualetti, G.; Del Tacca, M.; Danesi, R. 2006: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Molecular Cancer Therapeutics 5(6): 1387-1395

Arnett, D., K.; Claas, S., A. 2004: Pharmacogenetics of antihypertensive treatment. Drug Development Research 62(3): 191-199

Müller, D.J.; Muglia, P.; Fortune, T.; Kennedy, J.L. 2004: Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research 49(4): 309-329

Macciardi, F.; Martinelli Boneschi, F.; Cohen, D. 2005: Pharmacogenetics of autoimmune diseases: research issues in the case of Multiple Sclerosis and the role of IFN-beta. Journal of Autoimmunity 25(Suppl): 1-5

Xie, H.; Griskevicius, L.; Ståhle, L.; Hassan, Z.; Yasar, U.; Rane, A.; Broberg, U.; Kimby, E.; Hassan, M. 2006: Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 27(1): 54-61

Ingelman-Sundberg, M. 2004: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences 25(4): 193-200

Cascorbi, I. 2003: Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. European Journal of Clinical Investigation 33(Suppl): 17-22

De Bruin, M.L.; van Puijenbroek, E.P.; Bracke, M.; Hoes, A.W.; Leufkens, H.G.M. 2006: Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiology and Drug Safety 15(2): 99-105

Ingelman-Sundberg, M.; Rodriguez-Antona, C. 2005: Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 360(1460): 1563-1570

Haas, D.W.; Ribaudo, H.J.; Kim, R.B.; Tierney, C.; Wilkinson, G.R.; Gulick, R.M.; Clifford, D.B.; Hulgan, T.; Marzolini, C.; Acosta, E.P. 2004: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 18(18): 2391-2400

Wolschke, C.; Goekkurt, E.; Al-Batran, S-Eddin.; Hossfeld, D.Kurt.; Stoehlmacher, J. 2005: Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases. Onkologie 28(11): 589-592

Montagna, P.; Pierangeli, G.; Cevoli, S.; Mochi, M.; Cortelli, P. 2005: Pharmacogenetics of headache treatment. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 26(Suppl): S143-S147

Charasson, V.; Bellott, R.; Meynard, D.; Longy, M.; Gorry, P.; Robert, J. 2004: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clinical Pharmacology and Therapeutics 76(6): 528-535

Smith, N.F.; Figg, W.D.; Sparreboom, A. 2006: Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicology in Vitro: An International Journal Published in Association with Bibra 20(2): 163-175

Ando, M.; Hasegawa, Y.; Ando, Y. 2005: Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Investigational new Drugs 23(6): 539-545

Ordovas, J.M. 2004: Pharmacogenetics of lipid diseases. Human Genomics 1(2): 111-125

McGOUGH, J.; McCRACKEN, J.; Swanson, J.; Riddle, M.; Kollins, S.; Greenhill, L.; Abikoff, H.; Davies, M.; Chuang, S.; Wigal, T.; Wigal, S.; Posner, K.; Skrobala, A.; Kastelic, E.; Ghuman, J.; Cunningham, C.; Shigawa, S.; Moyzis, R.; Vitiello, B. 2006: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 45(11): 1314-1322

Cooke, G.E. 2006: Pharmacogenetics of multigenic disease: heart disease as an example. Vascular Pharmacology 44(2): 66-74

Di Paolo, A.; Danesi, R.; Del Tacca, M. 2004: Pharmacogenetics of neoplastic diseases: new trends. Pharmacological Research 49(4): 331-342

Rocha, J.C.C.; Cheng, C.; Liu, W.; Kishi, S.; Das, S.; Cook, E.H.; Sandlund, J.T.; Rubnitz, J.; Ribeiro, R.; Campana, D.; Pui, C.-H.; Evans, W.E.; Relling, M.V. 2005: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12): 4752-4758

Draganov, D.I.; La Du, B.N. 2004: Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Archives of Pharmacology 369(1): 78-88

Ribaudo, H.J.; Haas, D.W.; Tierney, C.; Kim, R.B.; Wilkinson, G.R.; Gulick, R.M.; Clifford, D.B.; Marzolini, C.; Fletcher, C.V.; Tashima, K.T.; Kuritzkes, D.R.; Acosta, E.P. 2006: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 42(3): 401-407

Malhotra, A.K.; Murphy, G.M.; Kennedy, J.L. 2004: Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 161(5): 780-796

Glatt, H.; Meinl, W. 2004: Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn-Schmiedeberg's Archives of Pharmacology 369(1): 55-68

Lesch, K.P.; Gutknecht, L. 2005: Pharmacogenetics of the serotonin transporter. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29(6): 1062-1073

Evans, W.E. 2004: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Therapeutic Drug Monitoring 26(2): 186-191

De Ridder, L.; Van Dieren, J.M.; Van Deventer, H.J.H.; Stokkers, P.C.F.; Van der Woude, J.C.J.; Van Vuuren, A.J.; Benninga, M.A.; Escher, J.C.; Hommes, D.W. 2006: Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Alimentary Pharmacology and Therapeutics 23(8): 1137-1141

Sparreboom, A.; Marsh, S.; Mathijssen, R.H.J.; Verweij, J.; McLeod, H.L. 2004: Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational New Drugs 22(3): 285-289

Reynolds, G.P.; Yao, Z.; Zhang, X.; Sun, J.; Zhang, Z. 2005: Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology 15(2): 143-151

Sadée, W.; Dai, Z. 2005: Pharmacogenetics/genomics and personalized medicine. Human Molecular Genetics 14 Spec No. 2: R207-R214

Humphries, S.E.; Hingorani, A. 2006: Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease. Vascular Pharmacology 44(2): 119-125

Gurwitz, D.; Rehavi, M. 2005: Pharmacogenetics: towards personalized medicine. Harefuah 144(10): 711

Foss, E.; Bedalov, A. 2006: Pharmacogenetics: yeast lead the way. Chemistry and Biology 13(3): 236-238

Robert, J. 2006: Pharmacogenetique et pharmacogenomie. Bulletin du Cancer 93(Sp. Iss. SI): 113-123

Rosmond, R. 2004: Pharmacogenomic approaches in antidiabetic drug development. Drug Development Research 62(3): 207-212

Ranganathan, P.; Eisen, S. 2004: Pharmacogenomic approaches to therapies in rheumatic diseases. Drug Development Research 62(3): 161-171

Marsh, S.; Xiao, M.; Yu, J.; Ahluwalia, R.; Minton, M.; Freimuth, R.R.; Kwok, P.-Y.; McLeod, H.L. 2004: Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84(4): 661-668

Jannetto, P.J.; Laleli-Sahin, E.; Wong, S.H. 2004: Pharmacogenomic genotyping methodologies. Clinical Chemistry and Laboratory Medicine 42(11): 1256-1264

Boyer, J.; Allen, W.L.; McLean, E.G.; Wilson, P.M.; McCulla, A.; Moore, S.; Longley, D.B.; Caldas, C.; Johnston, P.G. 2006: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Research 66(5): 2765-2777

Carson, J.P.; Zhang, N.; Frampton, G.M.; Gerry, N.P.; Lenburg, M.E.; Christman, M.F. 2004: Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Research 64(6): 2096-2104

Golden, T.R.; Hubbard, A.; Morten, K.J.; Hinerfeld, D.; Melov, S. 2005: Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy. Free Radical Biology and Medicine 39(2): 152-163

Xu, G.; Zhang, W.; Bertram, P.; Zheng, X.F.; McLeod, H. 2004: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. International Journal of Oncology 24(4): 893-900

Isaev, V.A. 2005: Pharmacogenomical aspects of gastroesophageal reflux disease. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 2005(6): 33-36

Binder, E.B.; Holsboer, F. 2006: Pharmacogenomics and antidepressant drugs. Annals of Medicine 38(2): 82-94

Siest, G.ér.; Marteau, J.-B.; Maumus, S.; Berrahmoune, H.; Jeannesson, E.; Samara, A.; Batt, A.-M.; Visvikis-Siest, S. 2005: Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology 527(1-3): 1-22

Yan, Q. 2005: Pharmacogenomics and systems biology of membrane transporters. Molecular Biotechnology 29(1): 75-88

Suarez-Kurtz, G. 2005: Pharmacogenomics in admixed populations. Trends in Pharmacological Sciences 26(4): 196-201

Petros, W.P.; Evans, W.E. 2004: Pharmacogenomics in cancer therapy: is host genome variability important?. Trends in Pharmacological Sciences 25(9): 457-464

Shah, R.; Darne, B.; Atar, D.; Abadie, E.; Adams, K.F.; Zannad, F. 2004: Pharmacogenomics in cardiovascular clinical trials. Fundamental and Clinical Pharmacology 18(6): 705-708

Carlquist, J., F.; Anderson, J., L. 2004: Pharmacogenomics in cardiovascular medicine. Drug Development Research 62(3): 180-190

Russo, A.; Corsale, S.; Cammareri, P.; Agnese, V.; Cascio, S.; Di Fede, G.; Macaluso, M.; Bazan, V. 2005: Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy. Journal of Cellular Physiology 204(3): 742-749

Shaw, D.; Russell, J., A.; Walley, K., R. 2005: Pharmacogenomics in sepsis and septic shock. Drug Development Research 64(4): 181-194

Haas, D.W. 2004: Pharmacogenomics of antiretroviral therapy. Drug Development Research 62(3): 213-220

Mellen, P.B.; Herrington, D.M. 2005: Pharmacogenomics of blood pressure response to antihypertensive treatment. Journal of Hypertension 23(7): 1311-1325

Schmitz, G.; Langmann, T. 2006: Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology 44(2): 75-89

Nguyen, H.; Tran, A.; Lipkin, S.; Fruehauf, J.P. 2006: Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Investigation 24(6): 630-639

Ishikawa, T.; Onishi, Y.; Hirano, H.; Oosumi, K.; Nagakura, M.; Tarui, S. 2004: Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biological and Pharmaceutical Bulletin 27(7): 939-948

Cascorbi, I.; Paul, M.; Kroemer, H.K. 2004: Pharmacogenomics of heart failure -- focus on drug disposition and action. Cardiovascular Research 64(1): 32-39

König, Jörg.; Seithel, A.; Gradhand, U.; Fromm, M.F. 2006: Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Archives of Pharmacology 372(6): 432-443

Nguyen, T.V.; Eisman, J.A. 2006: Pharmacogenomics of osteoporosis: opportunities and challenges. Journal of Musculoskeletal and Neuronal Interactions 6(1): 62-72

Nair, S.; Xu, C.; Shen, G.; Hebbar, V.; Gopalakrishnan, A.; Hu, R.; Jain, M.R.; Lin, W.; Keum, Y.-S.; Liew, C.; Chan, J.Y.; Kong, A.-N.T. 2006: Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharmaceutical Research 23(11): 2621-2637

Cunningham, S.; Graham, C.; Hutchinson, M.; Droogan, A.; O'Rourke, K.; Patterson, C.; McDonnell, G.; Hawkins, S.; Vandenbroeck, K. 2005: Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clinical Pharmacology and Therapeutics 78(6): 635-646

Kajinami, K.; Akao, H.; Polisecki, E.; Schaefer, E.J. 2005: Pharmacogenomics of statin responsiveness. American Journal of Cardiology 96(9a): 65k-70k; Discussion 34k-35k

Ishikawa, T.; Tamura, A.; Saito, H.; Wakabayashi, K.; Nakagawa, H. 2005: Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Die Naturwissenschaften 92(10): 451-463

Liu, S.; Bishop, W.R.; Dasmahapatra, B.; Wang, Y. 2004: Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance. Drug Development Research 62(3): 254-272

Danenberg, P.V. 2004: Pharmacogenomics of thymidylate synthase in cancer treatment. Frontiers in Bioscience: a Journal and Virtual Library 9: 2484-2494

Lunshof, J.; De-Wert, G. 2004: Pharmacogenomics, drug development, and ethics: Some points to consider. Drug Development Research 62(2): 112-116

Brien, J.Anne, E. 2003: Pharmacogenomics: Clinical and social implications. Journal of Pharmacy Practice and Research 33(3): 224-227

Farinola, N.; Piller, N. 2005: Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. Lymphatic Research and Biology 3(2): 81-86

Piruzian, A.L. 2005: Pharmacogenomics: way to individual therapy. Eksperimental'naia i Klinicheskaia Farmakologiia 68(5): 59-67

Marsh, S.; McLeod, H.L. 2006: Pharmacogenomics: from bedside to clinical practice. Human Molecular Genetics 15(Special Issue 1): R89-R93

Zhu, H.; Zhou, C-shan.; Liao, Y-kui.; Bai, Y-yuan. 2004: Pharmacognostic identification of Cryptolepis buchanaii. Zhongguo Zhong Yao Za Zhi 29(7): 634-636

Jegede, I.A.; Kunle, O.F.; Ibrahim, J.A.; Ugbabe, G.; Okogun, J.I. 2005: Pharmacognostic investigation of leaves of Mitracarpus vilosus (SW) DC. African Journal of Biotechnology 4(9): 957-959

Edwin, E.; Sheeja, E. 2005: Pharmacognostic preliminary phytochemical studies on Hibiscus rosa-sinensis. Indian Journal of Natural Products 21(4): 43-45

Kumar, S.; Taneja, R.; Sharma, A. 2006: Pharmacognostic standardization of Turnera aphrodisiaca Ward. Journal of Medicinal Food 9(2): 254-260

Bhogankar, P.Y.; Devarkar, V.D. 2002: Pharmacognostic studies in some asteraceous ethnomedicinal plants of Korkus of Melghat, Dist. Amravati, (M.S.). BRI'S Journal of Advances in Science and Technology 5(1-2): 28-32

Suseela, L. 2005: Pharmacognostic studies on Asystasia gangetica (Acanthaceae). Journal of Phytological Research 18(2): 191-198

Liao, Y-kui.; Jin, W-rong.; Huang, M-chun. 2005: Pharmacognostic studies on Desmodium gyrans. Zhongguo Zhong Yao Za Zhi 30(3): 175-177

Bai, L.; Jiang, H.; Kang, T.; Zhang, H.; Jiang, Z.; Zhao, Z. 2004: Pharmacognostical evaluation of Arctii fructus (5) chemical constituents from fruits of Amorpha fruticosa. Natural Medicines 58(6): 275-277

Manjoosha Srivastava; Sharad Srivastava; Sayyada Khatoon; Rawat, A.K.S.; Shanta Mehrotra; Palpu Pushpangadan 2006: Pharmacognostical evaluation of Cassia angustifolia seeds. Pharmaceutical Biology 44(3): 202-207

Tomari, N.; Ishizuka, Y.; Moriya, A.; Kojima, S.; Deyama, T.; Coskun, M.; Tu, P.; Mizukami, H. 2003: Pharmacognostical studies of cistanchis herba (IV) phylogenetic relationship of the Cistanche plants based on plastid rps2 gene and rpl16-rpl14 intergenic spacer region sequence. Natural Medicines 57(6): 233-237

Antman, E.M.; Van de Werf, F. 2004: Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation 109(21): 2480-2486

Yokogawa, K.; Toshima, K.; Yamoto, K.; Nishioka, T.; Sakura, N.; Miyamoto, K-ichi. 2006: Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol. Biological and Pharmaceutical Bulletin 29(6): 1229-1233

Dzodic, R.; Gomez-Abuin, G.; Rougier, P.; Bonnay, M.; Ardouin, P.; Gouyette, A.; Rixe, O.; Ducreux, M.; Munck, J-Nicolas. 2004: Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anti-Cancer Drugs 15(6): 647-650

Shimada, T.; Nomura, M.; Yokogawa, K.; Endo, Y.; Sasaki, T.; Miyamoto, K-ichi.; Yonemura, Y. 2005: Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. Journal of Pharmacy and Pharmacology 57(2): 177-181

Leung, C-Bon.; Szeto, C-Chun.; Ho, C-Shun.; Law, W-Keung.; Lam, C.Wai-Kei.; Li, P.Kam-Tao. 2005: Pharmacokinetic advantages of two-hour post-dose cyclosporin a level for the therapeutic drug monitoring in stable Chinese kidney transplant recipients. Nephron. Clinical Practice 99(3): C68-C72

Nakajou, K.; Horiuchi, S.; Sakai, M.; Haraguchi, N.; Otagiri, M. 2004: Pharmacokinetic analysis of advanced glycation end products (AGE). Yakugaku Zasshi 124(Suppl 4): 269-272

Higaki, K.; Ishii, M.; Esumi, H.; Kanayama, M.; Ogawara, K-I.; Kimura, T. 2003: Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 33(11): 1097-1108

Nishida, C.; Ogawara, K-I.; Kimura, T.; Higaki, K. 2004: Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics. III: mechanisms for sinusoidal efflux of 4-methylumbelliferone sulfate. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 34(5): 439-448

Okumura, N.; Fukushima, A.; Igarashi, A.; Sumi, T.; Yamagishi, T.; Ueno, H. 2006: Pharmacokinetic analysis of platelet-activating factor in the tears of guinea pigs with allergic conjunctivitis. Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 22(5): 347-352

Moriwaki, T.; Yasui, H.; Yamamoto, A. 2004: Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Pharmaceutical Research 21(6): 1055-1064

Ishida, K.; Takaai, M.; Hashimoto, Y. 2006: Pharmacokinetic analysis of transcellular transport of quinidine across monolayers of human intestinal epithelial Caco-2 cells. Biological and Pharmaceutical Bulletin 29(3): 522-526

Timby, E.; Balgård, M.; Nyberg, S.; Spigset, O.; Andersson, A.; Porankiewicz-Asplund, J.; Purdy, R.H.; Zhu, D.; Bäckström, Törn.; Poromaa, I.Sundström. 2005: Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology 186(3): 414-424

Rachmawati, H.; Beljaars, L.; Reker-Smit, C.; Van Loenen-Weemaes, A-miek.M.; Hagens, W.I.; Meijer, D.K.F.; Poelstra, K. 2004: Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharmaceutical Research 21(11): 2072-2078

Leyland Jones, B. 2004: Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. EJC Suppls 2(5): 9-12

Eckel, F.; von Delius, S.; Mayr, M.; Dobritz, M.; Fend, F.; Hosius, C.; Schleyer, E.; Schulte-Frohlinde, E.; Schmid, R.M.; Lersch, C. 2005: Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 69(5): 363-371

Song, H.; Zhang, J.; Han, Z.; Zhang, X.; Li, Z.; Zhang, L.; Fu, M.; Lin, C.; Ma, J. 2005: Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer ChemoTherapy and Pharmacology 57(5): 591-598

Scholtz, H.E.; Pretorius, S.G.; Wessels, D.H.; Becker, R.H.A. 2005: Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48(10): 1988-1995

Britzi, M.; Perucca, E.; Soback, S.; Levy, R.é H.; Fattore, C.; Crema, F.; Gatti, G.; Doose, D.R.; Maryanoff, B.E.; Bialer, M. 2005: Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 46(3): 378-384

Atsumi, M.; Kawakami, J.; Sugiyama, E.; Kotaki, H.; Sawada, Y.; Sato, H.; Yamada, Y.; Iga, T. 2003: Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats. Synapse 50(2): 110-116

Stein, D.S.; Lou, Y.; Johnson, M.; Randall, S.; Blanche, S. 2004: Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children. Journal of Clinical Pharmacology 44(11): 1301-1308

Mazzei, T.; Cassetta, M.I.; Fallani, S.; Arrigucci, S.; Novelli, A. 2006: Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. International Journal of Antimicrobial Agents 28(Suppl 1): S35-S41

Hoffman, A.; Stepensky, D.; Lavy, E.; Eyal, S.; Klausner, E.; Friedman, M. 2004: Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. International Journal of Pharmaceutics 277(1-2): 141-153

Blakey, G.E.; Lockton, J.A.; Perrett, J.; Norwood, P.; Russell, M.; Aherne, Z.; Plume, J. 2004: Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. British Journal of Clinical Pharmacology 57(2): 162-169

Ahmad, Z.; Pandey, R.; Sharma, S.; Khuller, G.K. 2006: Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. International Journal of Antimicrobial Agents 27(5): 409-416

Chan, P.L.S.; Nutt, J.G.; Holford, N.H.G. 2005: Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. Journal of Pharmacokinetics and Pharmacodynamics 32(3-4): 459-484

Kemp, S.F.; Fielder, P.J.; Attie, K.M.; Blethen, S.L.; Reiter, E.O.; Ford, K.M.; Marian, M.; Dao, L.N.; Lee, H.J.; Saenger, P. 2004: Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. Journal of Clinical Endocrinology and Metabolism 89(7): 3234-3240

Wang, L.H.; Begley, J.; St Claire, R.L.; Harris, J.; Wakeford, C.; Rousseau, F.S. 2004: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. Aids Research and Human Retroviruses 20(11): 1173-1182

Kamiya, H.; Akita, H.; Harashima, H. 2003: Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discovery Today 8(21): 990-996

Lalloo, A.; Chao, P.; Hu, P.; Stein, S.; Sinko, P.J. 2006: Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. Journal of Controlled Release: Official Journal of the Controlled Release Society 112(3): 333-342

Yu, K.-S.; Bae, K.-S.; Shon, J.-H.; Cho, J.-Y.; Yi, S.-Y.; Chung, J.-Y.; Lim, H.-S.; Jang, I.-J.; Shin, S.-G.; Song, K.-S.; Moon, B.-S. 2004: Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. Journal of Clinical Pharmacology 44(1): 73-82

Wu, W-Mei.; Buchwald, P.; Mori, N.; Ji, F.; Wu, J.; Bodor, N. 2005: Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics. Pharmaceutical Research 22(12): 2035-2044

Ginsberg, G.; Hattis, D.; Russ, A.; Sonawane, B. 2005: Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environmental Health Perspectives 113(9): 1243-1249

Andersson, K.-E.; Mulhall, J.P.; Wyllie, M.G. 2006: Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Bju International 97(2): 311-315

Huang, X-Hui.; Qiu, F-Rong.; Xie, H-Tang.; Li, J. 2005: Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. Journal of Cardiovascular Pharmacology 46(6): 863-869

Damy, T.; Pousset, F.ço.; Caplain, H.; Hulot, J.-S.éb.; Lechat, P. 2004: Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundamental and Clinical Pharmacology 18(1): 113-123

Watanabe, H.; Kosuge, K.; Nishio, S.; Yamada, H.; Uchida, S.; Satoh, H.; Hayashi, H.; Ishizaki, T.; Ohashi, K. 2004: Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sciences 76(3): 281-292

Krzyzanski, W.; Jusko, W.J.; Wacholtz, M.C.; Minton, N.; Cheung, W.K. 2005: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 26(3-4): 295-306

Ramakrishnan, R.; Cheung, W.K.; Wacholtz, M.C.; Minton, N.; Jusko, W.J. 2004: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. Journal of Clinical Pharmacology 44(9): 991-1002

Yun, H.-Y.; Park, H.-C.; Kang, W.; Kwon, K.-I. 2006: Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. Journal of Clinical Pharmacy and Therapeutics 31(5): 469-476

Huang, X-Hui.; Qiu, F-Rong.; Xie, H-Tang.; Li, J. 2005: Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions. European Journal of Drug Metabolism and Pharmacokinetics 30(1-2): 121-126

Chen, Z-Yang.; Xie, H-Tang.; Zheng, Q-Shan.; Sun, R-Yuan.; Hu, G. 2006: Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. European Journal of Drug Metabolism and Pharmacokinetics 31(1): 27-33

Almeida, L.; Soares-da-Silva, Pício. 2003: Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. Journal of Clinical Pharmacology 43(12): 1350-1360

Kamei, J.; Saitoh, A.; Asano, T.; Nakamura, R.; Ichiki, H.; Iiduka, A.; Kubo, M. 2005: Pharmacokinetic and pharmacodynamic profiles of the antitussive principles of Glycyrrhizae radix (licorice), a main component of the Kampo preparation Bakumondo-to (Mai-men-dong-tang). European Journal of Pharmacology 507(1-3): 163-168

Alfinito, P.D.; Huselton, C.; Chen, X.; Deecher, D.C. 2006: Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Research 1098(1): 71-78

Gretler, D.D. 2003: Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clinical Therapeutics 25(10): 2564-2574

Gretler, D.D.; Guerciolini, R.; Williams, P.J. 2004: Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clinical Therapeutics 26(3): 390-398

Bergman, A.J.; Stevens, C.; Zhou, Y.; Yi, B.; Laethem, M.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanaka, W.; Zeng, W.; Tanen, M.; Wang, A.Q.; Chen, L.; Winchell, G.; Davies, M.J.; Ramael, S.; Wagner, J.A.; Herman, G.A. 2006: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics 28(1): 55-72

Venkatesan, N.; Yoshimitsu, J.; Ohashi, Y.; Ito, Y.; Sugioka, N.; Shibata, N.; Takada, K. 2006: Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs. International Journal of Pharmaceutics 310(1-2): 46-52

Shelton, M.J.; Wire, M.B.; Lou, Y.; Adamkiewicz, B.; Min, S.S. 2006: Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrobial Agents and ChemoTherapy 50(3): 928-934

Stoltz, R.; Cyong, J-Chol.; Shah, A.; Parisi, S. 2004: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. Journal of Clinical Pharmacology 44(5): 520-531

Takemoto, S.; Nishikawa, M.; Takakura, Y. 2005: Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice. Pharmaceutical Research 22(3): 419-426

Siqueira, R.C.; Filho, E.R.; Fialho, S.íl.L.; Lucena, L.R.; Filho, A.M.; Haddad, A.ôn.; Jorge, R.; Scott, I.U.; Cunha, A.d.S. 2006: Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system: a pilot study. OPHTHALMOLOGICA. Journal International d'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde 220(5): 338-342

Theng, J.T.S.; Ti, S-Ei.; Zhou, L.; Lam, K-Wai.; Chee, S.Phaik.; Tan, D.; Ti, S.Ei. 2003: Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. IOVS Investigative Ophthalmology and Visual Science 44(11): 4895-4899

Murakami, Y.; Takamatsu, H.; Noda, A.; Osoda, K.; Ichise, R.; Tatsumi, M.; Tabata, K.; Sawamoto, T.; Nishimura, S. 2004: Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 45(11): 1946-1949

Sung, W.-C.; Chen, S.-H. 2006: Pharmacokinetic applications of capillary electrophoresis: a review on recent progress. Electrophoresis 27(1): 257-265

Tang, L.; Persky, A.M.; Hochhaus, G.ün.; Meibohm, B. 2004: Pharmacokinetic aspects of biotechnology products. Journal of Pharmaceutical Sciences 93(9): 2184-2204

Kubanova, A.A.; Kabanova, I.A. 2005: Pharmacokinetic aspects of evaluation of the efficacy and safety of pharmaceutical products. Vestnik Dermatologii i Venerologii 3: 41-43

Tagarro, I.; Vauzelle-Kervroedan, F.; Díez, M.Carmen. 2004: Pharmacokinetic assessment of a fast-release orodispersible tramadol tablet compared to a conventional tramadol capsule. Arzneimittel-Forschung 54(5): 293-297

Lanao, J.é M.; Calvo, M.V.; Mesa, J.é A.; Martín-Suárez, A.; Carbajosa, M.T.; Miguelez, F.; Domínguez-Gil, A. 2004: Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. Journal of Antimicrobial ChemoTherapy 54(1): 193-198

Fan-Wen-Yuan; Wu-Zheng-Hong; Ping-Qi-Neng; Guo-Jian-Xin; Tu-Qiu-Rong; Gao-Hao; Jiang-Jie; Cheng-Juan; Zhou-Jing 2005: Pharmacokinetic behavior and relative bioavailability of propylthiouracil sustained-release tablets vs market tablets in dogs. Zhongguo Xinyao yu Linchuang Zazhi 24(7): 515-518

He, L.; Wang, S. 2003: Pharmacokinetic behavior and tissue distribution of verapamil and its enantiomers in rats by HPLC. Archives of Pharmacal Research 26(9): 763-767

Shi, Z.; Zhang, Q.; Jiang, X. 2005: Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol. Life Sciences 77(20): 2574-2583

Regazzi, M.B.; Iacona, I.; Avanzini, M.Antonietta.; Arcaini, L.; Merlini, G.; Perfetti, V.; Zaja, F.; Montagna, M.; Morra, E.; Lazzarino, M. 2005: Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Therapeutic Drug Monitoring 27(6): 785-792

Renier, D.; Bellato, P.; Bellini, D.; Pavesio, A.; Pressato, D.; Borrione, A. 2005: Pharmacokinetic behaviour of ACP gel, an autocrosslinked hyaluronan derivative, after intraperitoneal administration. Biomaterials 26(26): 5368-5374

Müller, T.; Erdmann, C.; Muhlack, S.; Bremen, D.; Przuntek, H.; Goetze, O.; Woitalla, D. 2006: Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Journal of Neural Transmission 113(10): 1441-1448

Lee, J.H.; Suh, O.K.; Lee, M.G. 2004: Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Archives of Pharmacal Research 27(7): 693-712

Sugarbaker, P.H.; Stuart, O.A.; Carmignani, C.P. 2006: Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer ChemoTherapy and Pharmacology 57(5): 703-708

Bae, S.K.; Yang, S.H.; Lee, S.J.; Kwon, J.W.; Kim, W.B.; Lee, D.C.; Lee, M.G. 2005: Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 25(2-3): 337-345

Shim, H.J.; Kim, Y.C.; Kim, E.J.; Kim, D.G.; Kwon, J.W.; Kim, W.B.; Lee, M.G. 2004: Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. Biopharmaceutics and Drug Disposition 25(3): 137-142

Kim, Y.C.; Kwon, J.W.; Kim, W.B.; Lee, I.; Lee, M.G. 2004: Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. Journal of Pharmaceutical Sciences 93(9): 2374-2387

Kim, Y.C.; Shim, H.J.; Lee, J.H.; Kim, D.S.; Kwon, J.W.; Kim, W.B.; Lee, I.; Lee, M.G. 2005: Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Biopharmaceutics and Drug Disposition 26(7): 309-320

Chung, H.J.; Lee, M.G. 2006: Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate. Biopharmaceutics and Drug Disposition 27(7): 345-351

Hamada, A.; Aoki, A.; Terazaki, H.; Ito, K.; Yokoo, K.; Sasaki, Y.; Saito, H. 2005: Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient. Therapeutic Drug Monitoring 27(4): 536-538

Bae, S.K.; Lee, S.J.; Lee, J.Y.; Lee, Y.; Lee, I.; Kim, S.G.; Lee, M.G. 2004: Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. International Journal of Pharmaceutics 275(1-2): 227-238

Nomoto, M.; Nagai, M.; Nakatsuka, A.; Nishikawa, N.; Yabe, H.; Moritoyo, H.; Moritoyo, T.; Nomura, T. 2006: Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease. Journal of Neurology 253(Suppl 3): 53-59

Kashima, A.; Funahashi, M.; Fukumoto, K.; Komamura, K.; Kamakura, S.; Kitakaze, M.; Ueno, K. 2005: Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biological and Pharmaceutical Bulletin 28(10): 1934-1938

Fletcher, C.V.; Yogev, R.; Nachman, S.A.; Wiznia, A.; Pelton, S.; McIntosh, K.; Stanley, K. 2004: Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection. PharmacoTherapy 24(4): 453-459

Shibata, N.; Kageyama, M.; Kishida, T.; Kimura, K.; Yoshikawa, Y.; Kuwahara, T.; Toh, J.; Shirasaka, T.; Takada, K. 2003: Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. Biopharmaceutics and Drug Disposition 24(8): 335-344

Kornhuber, J.; Riederer, P.; Bleich, S.; Wiltfang, J.; Kraus, T.; Meineke, I. 2006: Pharmacokinetic characterization of amantadine in human brain tissue. Therapeutic Drug Monitoring 28(5): 693-695

Ahn, S.-H.; Jeon, S.-H.; Tsuruo, T.; Shim, C.-K.; Chung, S.-J. 2004: Pharmacokinetic characterization of dehydroevodiamine in the rat brain. Journal of Pharmaceutical Sciences 93(2): 283-292

Aiba, T.; Ishida, K.; Yoshinaga, M.; Okuno, M.; Hashimoto, Y. 2005: Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biological and Pharmaceutical Bulletin 28(1): 114-119

Toffoli, G.; Sorio, R.; Basso, B.; Aita, P.; Corona, G.; Rupolo, M.; Ruolo, G.; Boiocchi, M. 2004: Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin. Journal of ChemoTherapy 16(2): 193-200

Zhong-Jing-Jie; Wang-Dong-Kai; Liu-Zheng-Xian 2005: Pharmacokinetic comparison of levofloxacin aspartate and other levofloxacin salts. Zhongguo Kangshengsu Zazhi 30(8): 494-497

Klous, M.G.; Huitema, A.D.R.; Rook, E.J.; Hillebrand, M.J.X.; Hendriks, V.M.; Van den Brink, W.; Beijnen, J.H.; Van Ree, J.M. 2005: Pharmacokinetic comparison of two methods of heroin smoking: 'chasing the dragon' versus the use of a heating device. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology 15(3): 263-269

Ducongé, J.; Rodríguez-Vera, L.; Valenzuela, C.; Alvarez, D.; Ramírez, O.; de la Luz-Hernández, K.R.; Rabeza-Legón, E.Y.; Casacó, A.; Fernández-Sánchez, E. 2005: Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 61(3): 142-148

Di, B.; Feng, N.; Liu, W. 2006: Pharmacokinetic comparisons of Shuang-Huang-Lian with the different combinations of its constitutional herbs. Journal of Ethnopharmacology 107(3): 401-405

Syvänen, S.; Xie, R.; Sahin, S.; Hammarlund-Udenaes, M. 2006: Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharmaceutical Research 23(4): 705-717

Kenny, J.R.; Grime, K. 2006: Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 36(5): 351-365

Perlik, F.; Masri, M., A.; Rost, M.; Kamarad, V. 2005: Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Biomedical Papers (Olomouc) 149(2): 309-313

Huang, C.Zhi.; Feng, P.; Li, Y.Fang.; Tan, K.Jun. 2005: Pharmacokinetic detection of penicillin excreted in urine using a totally internally reflected resonance light scattering technique with cetyltrimethylammonium bromide. Analytical and Bioanalytical Chemistry 382(1): 85-90

Iwahori, T.; Takeuchi, H.; Matsuno, N.; Johjima, Y.; Konno, O.; Nakamura, Y.; Hama, K.; Uchiyama, M.; Ashizawa, T.; Okuyama, K.; Nagao, T.; Abudoshukur, M.; Hirano, T.; Oka, K. 2005: Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplantation Proceedings 37(4): 1739-1740

Xie, Z.; Zhang, Y.; Xu, H.; Zhong, D. 2005: Pharmacokinetic differences between pantoprazole enantiomers in rats. Pharmaceutical Research 22(10): 1678-1684

Miura, M.; Tada, H.; Yasui-Furukori, N.; Uno, T.; Sugawara, K.; Tateishi, T.; Suzuki, T. 2004: Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. European Journal of Clinical Pharmacology 60(9): 623-628

Nave, R.; Gunawardena, K.A.; Zech, K.; Bethke, T.D. 2006: Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. International Journal of Clinical Pharmacology and Therapeutics 44(1): 1-7

Bruce, R.Douglas.; Altice, F.L.; Gourevitch, M.N.; Friedland, G.H. 2006: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. Journal of Acquired Immune Deficiency Syndromes 41(5): 563-572

Back, D.; Gibbons, S.; Khoo, S. 2003: Pharmacokinetic drug interactions with nevirapine. Journal of Acquired Immune Deficiency Syndromes 34(Suppl): S8-S14

Van den Bongard, H.J.G.D.ée.; Sparidans, R.W.; Critchley, D.J.P.; Beijnen, J.H.; Schellens, J.H.M. 2004: Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Investigational new Drugs 22(2): 151-158

Swart, P.J.; Krauwinkel, W.J.J.; Smulders, R.A.; Smith, N.N. 2006: Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic and Clinical Pharmacology and Toxicology 99(1): 33-36

Getman, K.E.; Balthasar, J.P. 2005: Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. Journal of Pharmaceutical Sciences 94(4): 718-729

Shah, A.; DeGroot, T.; Apseloff, G. 2006: Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. Journal of Clinical Pharmacology 46(10): 1139-1145

Skowron, G.; Leoung, G.; Hall, D.B.; Robinson, P.; Lewis, R.; Grosso, R.; Jacobs, M.; Kerr, B.; MacGregor, T.; Stevens, M.; Fisher, A.; Odgen, R.; Yen-Lieberman, B. 2004: Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. Journal of Acquired Immune Deficiency Syndromes 35(4): 351-358

Malonne, H.; Sonet, B.; Streel, B.; Lebrun, S.; De Niet, S.; Sereno, A.; Vanderbist, F. 2004: Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. British Journal of Clinical Pharmacology 57(3): 270-278

Gandhi, R.; Kaul, C.L.; Panchagnula, R. 2004: Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers: a single dose study. International Journal of Pharmaceutics 270(1-2): 1-8

Al-Saidan, S.M.; Krishnaiah, Y.S.R.; Satyanarayana, V.; Bhaskar, P.; Karthikeyan, R.S. 2004: Pharmacokinetic evaluation of guar gum-based three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 58(3): 697-703

Bagchus, W.M.; Smeets, J.M.W.; Verheul, H.A.M.; De Jager-Van Der Veen, S.M.; Port, A.; Geurts, T.B.P. 2005: Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. Journal of Clinical Endocrinology and Metabolism 90(5): 2624-2630

Dailly, E.; Allavena, C.; Raffi, Fçois.; Jolliet, P. 2005: Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. British Journal of Clinical Pharmacology 60(1): 32-34

Wyska, E.; Szymura-Oleksiak, J.; Opoka, Włodzimierz.; Baś, Bław.; Niewiara, E.; Pomierny, L.; Dybała, Młgorzata.; Nowak, G. 2004: Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Polish Journal of Pharmacology 56(4): 479-484

Lee, S.Jung.; Bae, S.Kyung.; Kwon, J.Won.; You, M.; Lee, D.Chul.; Lee, M.Gull. 2005: Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. Journal of Pharmacy and Pharmacology 57(11): 1397-1405

Guaraldi, G.; Cocchi, S.; Codeluppi, M.; Di Benedetto, F.; Bonora, S.; Motta, A.; Luzi, K.; Pecorari, M.; Gennari, W.; Masetti, M.; Gerunda, G.E.; Esposito, R. 2006: Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplantation Proceedings 38(4): 1138-1140

van Giersbergen, P.L.M.; Halabi, A.; Dingemanse, J. 2006: Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. International Journal of Clinical Pharmacology and Therapeutics 44(3): 113-118

Cruciani, M.; Gatti, G.; Vaccher, E.; Di Gennaro, G.; Cinelli, R.; Bassetti, M.; Tirelli, U.; Bassetti, D. 2005: Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. Journal of Antimicrobial ChemoTherapy 55(4): 546-549

Anglicheau, D.; Flamant, M.; Schlageter, M.Hélène.; Martinez, F.; Cassinat, B.; Beaune, P.; Legendre, C.; Thervet, E. 2003: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 18(11): 2409-2414

Vlase, L.; Leucuta, A.; Farcau, D.; Nanulescu, M. 2006: Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharmaceutics and Drug Disposition 27(6): 285-289

Dieterle, W.; Mann, J. 2006: Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 44(7): 326-330

Dutreix, C.; Peng, B.; Mehring, G.; Hayes, M.; Capdeville, R.; Pokorny, R.; Seiberling, M. 2004: Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer ChemoTherapy and Pharmacology 54(4): 290-294

Aberg, J.A.; Rosenkranz, S.L.; Fichtenbaum, C.J.; Alston, B.L.; Brobst, S.W.; Segal, Y.; Gerber, J.G. 2006: Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. Aids 20(5): 725-729

Bae, S.Kyung.; Kim, E.Jung.; Chung, S.Jae.; Kim, S.Geon.; Lee, M.Gull. 2003: Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats. Journal of Pharmacy and Pharmacology 55(9): 1241-1249

Justesen, U.S.; Andersen, A.B.; Klitgaard, N.A.; Brøsen, K.; Gerstoft, J.; Pedersen, C. 2004: Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 38(3): 426-429

Kovarik, J.M.; Beyer, D.; Bizot, M.N.; Jiang, Q.; Allison, M.J.; Schmouder, R.L. 2005: Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. British Journal of Clinical Pharmacology 60(4): 434-437

Rengelshausen, J.; Burhenne, J.ür.; Fröhlich, M.; Tayrouz, Y.; Singh, S.K.; Riedel, K.-D.; Müller, O.; Hoppe-Tichy, T.; Haefeli, W.E.; Mikus, G.; Walter-Sack, I. 2004: Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. European Journal of Clinical Pharmacology 60(10): 709-715

Lin, W.; Hayakawa, T.; Yanaguimoto, H.; Kuzuba, M.; Obara, T.; Ding, G.; Cui, F.; Inotsume, N. 2004: Pharmacokinetic interaction of ibuprofen enantiomers in rabbits. Journal of Pharmacy and Pharmacology 56(3): 317-321

Hsyu, P-Hirr.; Lillibridge, J.; Daniels, E.; Kerr, B.M. 2005: Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharmaceutics and Drug Disposition 27(2): 61-68

Taekema-Roelvink, M.E.J.; Swart, P.J.; Kuipers, M.E.; Krauwinkel, W.J.J.; Visser, N.; Smulders, R.A. 2005: Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clinical Therapeutics 27(9): 1403-1410

Oh, Y.-H.; Han, H.-K. 2006: Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anion transporters in rats. Pharmacological Research 53(1): 75-79

Ikeda, H.; Murakami, T.; Takano, M.; Usui, T.; Kihira, K. 2005: Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. British Journal of Clinical Pharmacology 59(5): 593-597

Chien, S.; Bialer, M.; Solanki, B.; Verhaeghe, T.; Doose, D.R.; Novak, G.; Yao, C. 2006: Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 47(11): 1830-1840

la Porte, C.; Verweij-van Wissen, C.; van Ewijk, N.; Aarnoutse, R.; Koopmans, P.; Reiss, P.; Stek, M.; Hekster, Y.; Burger, D. 2005: Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. Journal of Clinical Pharmacology 45(2): 211-218

Higashi, Y.; Ikeda, Y.; Yamamoto, R.; Yamashiro, M.; Fujii, Y. 2005: Pharmacokinetic interaction with digoxin and glucocorticoids in rats detected by radio-immunoassay using a novel specific antiserum. Life Sciences 77(9): 1055-1067

Brennan-Benson, P.; Lyus, R.; Harrison, T.; Pakianathan, M.; Macallan, D. 2005: Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. Aids 19(14): 1541-1543

Glesby, M.J.; Aberg, J.A.; Kendall, M.A.; Fichtenbaum, C.J.; Hafner, R.; Hall, S.; Grosskopf, N.; Zolopa, A.R.; Gerber, J.G. 2005: Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical Pharmacology and Therapeutics 78(2): 143-153

Corsini, A.; Bellosta, S.; Davidson, M.H. 2005: Pharmacokinetic interactions between statins and fibrates. American Journal of Cardiology 96(9a): 44k-49k; Discussion 34k-35k

Adamis, G.; Papaioannou, M.G.; Giamarellos-Bourboulis, E.J.; Gargalianos, P.; Kosmidis, J.; Giamarellou, H. 2004: Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. International Journal of Antimicrobial Agents 23(2): 144-149

Khosravan, R.; Wu, J.-T.; Joseph-Ridge, N.; Vernillet, L. 2006: Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. Journal of Clinical Pharmacology 46(8): 855-866

Dieterle, W.; Corynen, S.; Vaidyanathan, S.; Mann, J. 2005: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. International Journal of Clinical Pharmacology and Therapeutics 43(11): 527-535

Ye-Zhi-Bin; Zhang-Yue; Wu-Zhao-Long 2004: Pharmacokinetic investigation of aristolochic acid A in normal rats. Fudan Xuebao 31(6): 562-564

Khayat, D.; Rixe, O.; Brunet, R.é; Goupil, A.; Bugat, R.; Harousseau, J.-L.; Ifrah, N.; Puozzo, C. 2004: Pharmacokinetic linearity of I.v. vinorelbine from an intra-patient dose escalation study design. Cancer ChemoTherapy and Pharmacology 54(3): 193-205

Shibutani, K.; Inchiosa, M.A.; Sawada, K.; Bairamian, M. 2005: Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. British Journal of Anaesthesia 95(3): 377-383

Song, L.; Prey, J.D.; Xue, J.; Kanter, P.; Manzotti, C.; Bombardelli, E.; Morazzoni, P.; Pendyala, L. 2005: Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma. Rapid Communications in Mass Spectrometry: Rcm 19(24): 3617-3625

Jiao, Z.; Shen, J.; Zhong, L-jin.; Yu, Y-qiu.; Zhong, M-kang. 2006: Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid. Yao Xue Xue Bao 41(3): 272-276

de la Motte, S.; Gianella-Borradori, A. 2004: Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. International Journal of Clinical Pharmacology and Therapeutics 42(4): 232-239

Marchand, S.; Chenel, M.; Lamarche, I.; Couet, W. 2005: Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis. Antimicrobial Agents and ChemoTherapy 49(9): 3702-3706

Murakami, Y.; Tanaka, T.; Murakami, H.; Tsujimoto, M.; Ohtani, H.; Sawada, Y. 2006: Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin a. British Journal of Clinical Pharmacology 61(6): 671-676

EL Desoky, E.S.; Fuseau, E.; EL Din Amry, S.; Cosson, V.ér. 2004: Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. European Journal of Clinical Pharmacology 59(11): 783-790

Ruiz-Carretero, P.; Merino-Sanjuán, M.; Nácher, A.; Casabó, V.G. 2004: Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 21(2-3): 217-223

Itoh, T.; Itagaki, S.; Sasaki, K.; Hirano, T.; Takemoto, I.; Iseki, K. 2004: Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats. Journal of Pharmacy and Pharmacology 56(6): 809-812

Ferraresso, M.; Ghio, L.; Zacchello, G.; Murer, L.; Ginevri, F.; Perfumo, F.; Zanon, G.Franco.; Fontana, I.; Amore, A.; Edefonti, A.; Vigano, S.; Cardillo, M.; Scalamogna, M. 2005: Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving A quadruple immunosuppressive regimen: the value of C2 blood levels. Transplantation 79(9): 1164-1168

Turner, J.V.; Maddalena, D.J.; Cutler, D.J. 2004: Pharmacokinetic parameter prediction from drug structure using artificial neural networks. International Journal of Pharmaceutics 270(1-2): 209-219

Su, M-Y.; Yu, H.J.; Carpenter, P.M.; McLaren, C.E.; Nalcioglu, O. 2005: Pharmacokinetic parameters analyzed from mr contrast enhancement kinetics of multiple malignant and benign breast lesions detected in the same patients. Technology in Cancer Research and Treatment 4(3): 255-263

Abou-Basha, L., I.; Wahman, L., F.; Gharib, H.A.; Tantway, W.H. 2005: Pharmacokinetic parameters and relative bioavailability of two tablet formulations of enalapril maleate. Instrumentation Science and Technology 33(1): 1-8

Zaidi, Z.; Bezzina, M.; Cherruault, Y. 2005: Pharmacokinetic parameters identification using the combined Alienor/Adomian methods. Kybernetes 34(7-8): 1142-1158

Lee, S.-Y.; Kim, Y.G.; Kim, H.-G.; Kim, J.-W. 2006: Pharmacokinetic parameters of bromperidol in Korean subjects. Human Psychopharmacology 21(6): 409-412

Weinling, E.; McDougall, S.; Andre, Fédéric.; Bianchetti, G.; Dubruc, C. 2006: Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundamental and Clinical Pharmacology 20(4): 397-403

Harmatz, P.; Kramer, W.G.; Hopwood, J.J.; Simon, J.; Butensky, E.; Swiedler, S.J. 2005: Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatrica . Supplement 94(447): 61-8; Discussion 57

Swan, S.K.; Alcorn, H.; Rodgers, A.; Hustad, C.M.; Ramsey, K.E.; Woll, S.; Skobieranda, F. 2006: Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. Journal of Clinical Pharmacology 46(2): 172-178

Chapple, C., R.; Chartier-Kastler, E. 2006: Pharmacokinetic profile of tamsulosin OCAS. BJU International 98(Suppl 2): 9-12

Stangier, J.; Eriksson, B.I.; Dahl, O.E.; Ahnfelt, L.; Nehmiz, G.; Stähle, H.; Rathgen, K.; Svärd, R. 2005: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Journal of Clinical Pharmacology 45(5): 555-563

Sun, H.K.; Ong, C.T.; Umer, A.; Harper, D.; Troy, S.; Nightingale, C.H.; Nicolau, D.P. 2005: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrobial Agents and ChemoTherapy 49(4): 1629-1632

Dai-Shu-Jia; Liao-Zhi; Liu-Xiu-Wen; Liang-Song-Ping; Tang-Zhong-Ming 2004: Pharmacokinetic profiles of huwentoxin-1 after epidural and intravenous administration in rats. Zhongguo Yaolixue Yu Dulixue Zazhi 18(5): 344-351

Rasetti-Escargueil, C.; Grangé, V. 2005: Pharmacokinetic profiles of two tablet formulations of piroxicam. International Journal of Pharmaceutics 295(1-2): 129-134

Narang, V.S.; Lulla, A.; Malhotra, G.; Purandare, S. 2005: Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers. Arzneimittel-Forschung 55(10): 598-603

Wacke, R.; Kundt, G.; Gock, M.; Klar, E.; Drewelow, B.; Schareck, W. 2006: Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. Transplantation Proceedings 38(3): 751-752

Kuti, J.L.; Nightingale, C.H.; Knauft, R.Frederic.; Nicolau, D.P. 2004: Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clinical Therapeutics 26(4): 493-501

Lebovitz, D.J.; Smith, P.G.; O'Riordan, M.; Reed, M.D. 2004: Pharmacokinetic properties and tolerability of single-dose terbutaline in patients with severe asthma treated in the pediatric intensive care unit. Current Therapeutic Research 65(1): 98-109

Kreuz, W.; Meili, E.; Peter-Salonen, K.; Dobrkovská, A.; Devay, J.; Haertel, S.; Krzensk, U.; Egbring, R. 2005: Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis 32(3): 239-246

Kapil, R.; Nolting, A.; Roy, P.; Fiske, W.; Benedek, I.; Abramowitz, W. 2004: Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Clinical Therapeutics 26(12): 2015-2025

Li, J.; Zhao, J.; Hamer-Maansson, J.E.; Andersson, T.; Fulmer, R.; Illueca, M.; Lundborg, P. 2006: Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. Clinical Therapeutics 28(3): 419-427

Piliero, P.J. 2004: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndromes 37(Suppl): S2

Escobar, Y.; Venturelli, C.R.; Hoyo-Vadillo, C. 2005: Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. Current Therapeutic Research 66(3): 238-246

Sakurai, Y.; Motohashi, H.; Ogasawara, K.; Terada, T.; Masuda, S.; Katsura, T.; Mori, N.; Matsuura, M.; Doi, T.; Fukatsu, A.; Inui, K-ichi. 2005: Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharmaceutical Research 22(12): 2016-2022

Yakovleva, I.I.; Timokhov, V.S. 2004: Pharmacokinetic simulation of different modes of renal replacement therapy. Anesteziologiya i Reanimatologiya 6: 16-23

Jung, L.L.; Ramanathan, R.K.; Egorin, M.J.; Jin, R.; Belani, C.P.; Potter, D.M.; Strychor, S.; Trump, D.L.; Walko, C.; Fakih, M.; Zamboni, W.C. 2004: Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer ChemoTherapy and Pharmacology 54(6): 487-496

Novakovic, J.; Wodzinska, J.; Tesoro, A.; Thiessen, J.J.; Spino, M. 2005: Pharmacokinetic studies of a novel 1,2,4-thiadiazole derivative, inhibitor of Factor XIIIa, in the rabbit by a validated HPLC method. Journal of Pharmaceutical and Biomedical Analysis 38(2): 293-297

Chu, K.O.; Wang, C.C.; Chu, C.Y.; Chan, K.P.; Rogers, M.S.; Choy, K.W.; Pang, C.P. 2006: Pharmacokinetic studies of green tea catechins in maternal plasma and fetuses in rats. Journal of Pharmaceutical Sciences 95(6): 1372-1381

Capacio, B.R.; Byers, C.E.; Merk, K.A.; Smith, J.R.; McDonough, J.H. 2004: Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. Drug and Chemical Toxicology 27(2): 95-110

Whitehouse, T.; Cepeda, J.A.; Shulman, R.; Aarons, L.; Nalda-Molina, R.; Tobin, C.; MacGowan, A.; Shaw, S.; Kibbler, C.; Singer, M.; Wilson, A.P.R. 2005: Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. Journal of Antimicrobial ChemoTherapy 55(3): 333-340

Camacho-Hübner, C.; Rose, S.; Preece, M.A.; Sleevi, M.; Storr, H.L.; Miraki-Moud, F.; Minuto, F.; Frystyk, J.; Rogol, A.; Allan, G.; Sommer, A.; Savage, M.O. 2006: Pharmacokinetic studies of recombinant human insulin-like growth factor i (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. Journal of Clinical Endocrinology and Metabolism 91(4): 1246-1253

Wada, K.; Takada, M.; Ueda, T.; Ochi, H.; Morishita, H.; Hanatani, A.; Nakatani, T. 2006: Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients. Circulation Journal: Official Journal of the Japanese Circulation Society 70(10): 1307-1311

Piette, M.; Evrard, B.; Frankenne, F.; Chiap, P.; Bertholet, P.; Castagne, D.; Foidart, J.-M.; Delattre, L.; Piel, G.ér. 2006: Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 28(3): 189-195

Saito, K.; Takeshita, K.; Anzai, K.; Ozawa, T. 2004: Pharmacokinetic study of acyl-protected hydroxylamine probe, 1-acetoxy-3-carbamoyl-2,2,5,5-tetramethylpyrrolidine, for in vivo measurements of reactive oxygen species. Free Radical Biology and Medicine 36(4): 517-525

Zuo, F.; Zhao, J.; Nakamura, N.; Gao, J.-Jing; Akao, T.; Hattori, M.; Oomiga, Y.; Kikuchi, Y. 2006: Pharmacokinetic study of benzoylmesaconine in rats using an enzyme immunoassay system. Journal of Natural Medicines 60(4): 313-321

Itoh, T. 2006: Pharmacokinetic study of cancer chemotherapy. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 126(9): 723-735

Lei, F.; Xing, D.-M.; Xiang, L.; Zhao, Y.-N.; Wang, W.; Zhang, L.-J.; Du, L.-J. 2003: Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. Journal of Chromatography. B Analytical Technologies in the Biomedical and Life Sciences 796(1): 189-194

Landry, R.; Jacobs, P.M.; Davis, R.; Shenouda, M.; Bolton, W.K. 2005: Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. American Journal of Nephrology 25(4): 400-410

Tian-Lei; Jiang-Juan-Juan; Huang-Yi-Ling; Hua-Lu; Kuang-Fu-Hua; Yi-Shi, L. 2006: Pharmacokinetic study of ibutilide injection in Chinese healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 25(7): 531-534

Liang, H.; Tang, H-wen.; Hao, X-shan.; Sun, H.; Li, W. 2005: Pharmacokinetic study of intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. Zhonghua Zhong Liu Za Zhi 27(7): 412-415

He, H-Bing.; Tang, X.; Cui, F-De. 2006: Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique. Yao Xue Xue Bao 41(5): 452-456

He, H.; Tang, X.; Cui, F. 2006: Pharmacokinetic study of ketoprofen isopropyl ester-loaded lipid microspheres in rat blood using microdialysis. Biological and Pharmaceutical Bulletin 29(4): 841-845

Periclou, A.; Ventura, D.; Rao, N.; Abramowitz, W. 2006: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clinical Pharmacology and Therapeutics 79(1): 134-143

Liang, L.S.; Wong, W.; Burt, H.M. 2005: Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. Journal of Pharmaceutical Sciences 94(6): 1204-1215

Ju-Yang; Lu-Li; Wu-Yong-Jie; Gao-Ming-Tang; Li-Wen-Guang; Min-Guang-Ning 2005: Pharmacokinetic study of novel recombinant human tumor necrosis factor-alpha (nrhTNF-alpha) in mice using ELISA. Zhongguo Yaolixue Tongbao 21(7): 847-851

Lee, S.-Y.; Oh, H.J.; Kim, J.W.; Kim, Y.G.; Moon, C.J.; Lee, E.H. 2006: Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Journal of Chromatography. B Analytical Technologies in the Biomedical and Life Sciences 839(1-2): 118-123

Cattel, L.; La Grotta, G.; Infante, L.; Passera, R.; Arpicco, S.; Brusa, P.; Bumma, C. 2003: Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. Farmaco 58(12): 1333-1338

Meng, Z.; Wang, W.; Xing, D.-M.; Lei, F.; Lan, J.-Q.; Du, L.-J. 2006: Pharmacokinetic study of p-coumaric acid in mouse after oral administration of extract of Ananas comosus L. leaves. Biomedical Chromatography: Bmc 20(9): 951-955

Jang, J.-Ok; Go, E.-Jung; Kim, N.-Hyung; Chung, S.-Yeon; Park, H.-Min; Lee, H.-Jeong 2005: Pharmacokinetic study of promethazine in Korean healthy subjects using a validated HPLC method. Journal of Applied Pharmacology 13(2): 118-122

Ido, A.; Moriuchi, A.; Kim, I.; Numata, M.; Nagata-Tsubouchi, Y.; Hasuike, S.; Uto, H.; Tsubouchi, H. 2004: Pharmacokinetic study of recombinant human hepatocyte growth factor administered in a bolus intravenously or via portal vein. Hepatology Research: the Official Journal of the Japan Society of Hepatology 30(3): 175-181

Autar, R.S.; Ananworanich, J.; Apateerapong, W.; Sankote, J.; Hill, A.; Hirschel, B.; Cooper, D.; Lange, J.; Phanuphak, P.; Ruxrungtham, K.; Burger, D. 2004: Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. Journal of Antimicrobial ChemoTherapy 54(4): 785-790

Droste, J.A.H.; Verweij-van Wissen, C.P.W.G.M.; Kearney, B.P.; Buffels, R.; Vanhorssen, P.J.; Hekster, Y.A.; Burger, D.M. 2005: Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrobial Agents and ChemoTherapy 49(2): 680-684

Ramenskaya, G.V.; Shich, E.V.; Arzamaszev, A.P.; Kukes, V.G. 2005: Pharmacokinetic study of the new domestic prolonged form naltrexone - Depo-tablets prodetoxon. Khimiko Farmatsevticheskii Zhurnal 39(1): 3-5

Wang, L.; Zhang, Z.; Yang, W. 2005: Pharmacokinetic study of trimebutine maleate in rabbit blood using in vivo microdialysis coupled to capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 39(3-4): 399-403

Veng-Pedersen, P.; Chapel, S.; Al-Huniti, N.H.; Schmidt, R.L.; Sedars, E.M.; Hohl, R.J.; Widness, J.A. 2004: Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharmaceutics and Drug Disposition 25(4): 149-156

Taguchi, M.; Nozawa, T.; Igawa, A.; Inoue, H.; Takesono, C.; Tahara, K.; Hashimoto, Y. 2005: Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. Biological and Pharmaceutical Bulletin 28(5): 876-881

Chueh, S-C.J.; Wang, S-M.; Lai, M-K.; Chen, J. 2004: Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. Transplantation Proceedings 36(7): 2058-2059

Zapater, P.; Lasso de la Vega, M.C.; Horga, J.F.; Such, J.; Frances, R.; Esteban, A.; Palazòn, J.M.; Carnicer, F.; Pascual, S.; Pérez-Mateo, M. 2004: Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Alimentary Pharmacology and Therapeutics 20(1): 29-36

Höcht, C.; Di Verniero, C.; Opezzo, J.A.W.; Bramuglia, G.F.; Taira, C.A. 2006: Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology 373(4): 310-318

Kihira, T.; Sato, J.; Shibata, T. 2004: Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of ChemoTherapy 10(2): 97-100

Pea, F.; Furlanut, M.; Stellini, R.; Bonardelli, S.; Signorini, L.; Pavan, F.; Matheis, A.; Portolani, N.; Lorenzotti, S.; Giulini, S.M.; Viale, P.; Carosi, G. 2006: Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery. International Journal of Antimicrobial Agents 27(1): 15-19

Ma, P.; Wang, Y.; van der Hoek, J.; Nedelman, J.; Schran, H.; Tran, L.-L.; Lamberts, S.W.J. 2005: Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical Pharmacology and Therapeutics 78(1): 69-80

Huntjens, D.R.H.; Danhof, M.; Della Pasqua, O.E. 2005: Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 44(7): 846-859

Almeida, L.; Vaz-da-Silva, M.; Silveira, P.; Falcão, A.; Maia, J.; Loureiro, A.; Torrão, L.; Machado, R.; Wright, L.; Soares-da-Silva, P.íc. 2004: Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clinical Neuropharmacology 27(1): 17-24

Lee, S.H.; Kwon, K.-i. 2004: Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. Archives of Pharmacal Research 27(7): 806-810

Ollerstam, A.; Visser, S.A.G.; Persson, A.H.; Eklund, G.ör.; Nilsson, L.B.; Forsberg, T.; Wiklund, S.J.; Gabrielsson, J.; Duker, G.ör.; Al-Saffar, A. 2006: Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 53(2): 174-183

Huang-Xiao-Hui; Qiu-Fu-Rong; Li-Jun 2005: Pharmacokinetic-pharmacodynamic modeling of irbesartan in healthy Chinese adult volunteers. Zhongguo Yaolixue Tongbao 21(6): 712-715

Yassen, A.; Olofsen, E.; Dahan, A.; Danhof, M. 2005: Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. Journal of Pharmacology and Experimental Therapeutics 313(3): 1136-1149

Audren, Fçois.; Tod, M.; Massin, P.; Benosman, R.; Haouchine, B.; Erginay, A.; Caulin, C.; Gaudric, A.; Bergmann, J-François. 2004: Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. IOVS Investigative Ophthalmology and Visual Science 45(10): 3435-3441

Ortega, F.át.; Quintana, A.; Suárez, E.; Lukas, J.C.; Jauregizar, N.; de la Fuente, L.; Lucero, M.L.; Gonzalo, A.; Orjales, A.; Calvo, R. 2005: Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model. Pharmaceutical Research 22(11): 1769-1782

McKay, I.D.H.; Voss, L.J.; Sleigh, J.W.; Barnard, J.P.; Johannsen, E.K. 2005: Pharmacokinetic-pharmacodynamic modeling the hypnotic effect of sevoflurane using the spectral entropy of the electroencephalogram. Anesthesia and Analgesia 102(1): 91-97

Friberg, L.E.; Isbister, G.K.; Duffull, S.B. 2006: Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. British Journal of Clinical Pharmacology 61(2): 177-190

Liu, P.; Rand, K.H.; Obermann, B.; Derendorf, H. 2005: Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. International Journal of Antimicrobial Agents 25(2): 120-129

Haritova, A.M.; Rusenova, N.V.; Parvanov, P.R.; Lashev, L.D.; Fink-Gremmels, J. 2006: Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys. Veterinary Research Communications 30(7): 775-789

Limosin, A.; Dupuis, A.; Lamarche, I.; Mimoz, O.; Paquereau, J.; Couet, W. 2004: Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. Journal of Antimicrobial ChemoTherapy 54(1): 187-192

Friberg, L.E.; Hassan, S.B.; Lindhagen, E.; Larsson, R.; Karlsson, M.O. 2005: Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 25(1): 163-173

Csajka, C.; Verotta, D. 2006: Pharmacokinetic-pharmacodynamic modelling: history and perspectives. Journal of Pharmacokinetics and Pharmacodynamics 33(3): 227-279

Höcht, C.; Di Verniero, C.; Opezzo, J.A.W.; Taira, C.A. 2004: Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. Naunyn-Schmiedeberg's Archives of Pharmacology 370(1): 1-8

Bhavnani, S.M.; Passarell, J.A.; Owen, J.S.; Loutit, J.S.; Porter, S.B.; Ambrose, P.G. 2006: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrobial Agents and ChemoTherapy 50(3): 994-1000

Silveira, P.; Vaz-da-Silva, M.; Almeida, L.; Maia, J.; Falcão, A.; Loureiro, A.; Torrão, L.; Machado, R.; Wright, L.; Soares-da-Silva, P.íc. 2003: Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. European Journal of Clinical Pharmacology 59(8-9): 603-609

Ng, C.M.; Joshi, A.; Dedrick, R.L.; Garovoy, M.R.; Bauer, R.J. 2005: Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharmaceutical Research 22(7): 1088-1100

Schuck, E.L.; Dalhoff, A.; Stass, H.; Derendorf, H. 2005: Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 33(Suppl 2): 22-28

Sugiura, M.; Ohno, Y.; Yamada, Y.; Suzuki, H.; Iga, T. 2004: Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by rhG-CSF in patients receiving antineoplastic drugs. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 124(9): 599-604

Al-Huniti, N.H.; Widness, J.A.; Schmidt, R.L.; Veng-Pedersen, P. 2004: Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. Journal of Pharmacology and Experimental Therapeutics 310(1): 202-208

Van der Post, J.P.; de Visser, S.J.; Schoemaker, R.C.; Cohen, A.F.; van Gerven, J.M.A. 2004: Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. Journal of Psychopharmacology 18(2): 221-227

Gupta, N.; Hoffman, R.P.; Veng-Pedersen, P. 2006: Pharmacokinetic/pharmacodynamic insulin-glucose analysis for differentiation of beta-cell function: an 18 month follow-up study in pre-pubertal lean and obese children. Biopharmaceutics and Drug Disposition 27(6): 257-265

Mohr, J.F.; Wanger, A.; Rex, J.H. 2004: Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagnostic Microbiology and Infectious Disease 48(2): 125-130

Roskos, L.K.; Lum, P.; Lockbaum, P.; Schwab, G.; Yang, B-Bing. 2006: Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. Journal of Clinical Pharmacology 46(7): 747-757

Stark, J.G.; Werner, S.; Homrighausen, S.; Tang, Y.; Krieg, M.; Derendorf, H.; Moellmann, H.; Hochhaus, G. 2006: Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. Journal of Pharmacokinetics and Pharmacodynamics 33(4): 441-459

Karlsson, M.O.; Anehall, T.; Friberg, L.E.; Henningsson, A.; Kloft, C.; Sandström, M.; Xie, R. 2005: Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic and Clinical Pharmacology and Toxicology 96(3): 206-211

Dubois, E.F.L.; Derks, M.G.M.; Schweitzer, D.H.; Zwinderman, A.H.; Dekhuijzen, P.N.R.; van Boxtel, C.J. 2004: Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. European Journal of Clinical Pharmacology 60(5): 315-328

Schaddelee, M.P.; Collins, S.D.; DeJongh, J.; de Boer, A.G.; Ijzerman, A.P.; Danhof, M. 2005: Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. European Journal of Pharmacology 514(2-3): 131-140

Zingmark, P-Henrik.; Edenius, C.; Karlsson, M.O. 2004: Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. British Journal of Clinical Pharmacology 58(4): 378-389

Paccaly, A.; Frick, A.; Ozoux, M-Laure.; Chu, V.; Rosenburg, R.; Hinder, M.; Shukla, U.; Jensen, B.K. 2006: Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. Journal of Clinical Pharmacology 46(1): 45-51

Park, S.I.; Felipe, C.R.; Machado, P.G.; Garcia, R.; Skerjanec, A.; Schmouder, R.; Tedesco-Silva, H.; Medina-Pestana, J.O. 2005: Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. Brazilian Journal of Medical and Biological Research 38(5): 683-694

Veal, G.J.; English, M.W.; Grundy, R.G.; Shakespeare, C.; Glaser, A.; Waters, F.; Holden, V.; O'Meara, A.; Michalski, A.; Howe, K.; Cole, S.; Boddy, A.V. 2004: Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer ChemoTherapy and Pharmacology 54(4): 295-300

Jilma-Stohlawetz, P.; Reiter, R.A.; Panzer, S.; Horvath, M.; Eppel, W.; Jilma, B. 2005: Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis 33(2): 135-140

Gandolf, A.Rae.; Papich, M.G.; Bringardner, A.B.; Atkinson, M.W. 2005: Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. American Journal of Veterinary Research 66(5): 767-771

Ananworanich, J.; Kosalaraksa, P.; Hill, A.; Siangphoe, U.; Bergshoeff, A.; Pancharoen, C.; Engchanil, C.; Ruxrungtham, K.; Burger, D. 2005: Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatric Infectious Disease Journal 24(10): 874-879

Abd El-Aty, A.M.; Goudah, A.; Abo El-Sooud, K.; El-Zorba, H.Y.; Shimoda, M.; Zhou, H.H. 2004: Pharmacokinetics and bioavailability of florfenicol following intravenous, intramuscular and oral administrations in rabbits. Veterinary Research Communications 28(6): 515-524

Zineh, I.; Beitelshees, A.L.; Gaedigk, A.; Walker, J.R.; Pauly, D.F.; Eberst, K.; Leeder, J.Steven.; Phillips, M.S.; Gelfand, C.A.; Johnson, J.A. 2004: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical Pharmacology and Therapeutics 76(6): 536-544

Kikura, M.; Morita, K.; Sato, S. 2004: Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. Pharmacological Research 49(3): 275-281

Newsted, J.L.; Beach, S.A.; Gallagher, S.P.; Giesy, J.P. 2006: Pharmacokinetics and acute lethality of perfluorooctanesulfonate (PFOS) to juvenile mallard and northern bobwhite. Archives of Environmental Contamination and Toxicology 50(3): 411-420

Davison, S.; Thipphawong, J.; Blanchard, J.; Liu, K.; Morishige, R.; Gonda, I.; Okikawa, J.; Adams, J.; Evans, A.; Otulana, B.; Davis, S. 2005: Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. Journal of Clinical Pharmacology 45(2): 177-184

Stathopoulos, G.P.; Boulikas, T.; Vougiouka, M.; Deliconstantinos, G.; Rigatos, S.; Darli, E.; Viliotou, V.; Stathopoulos, J.G. 2005: Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncology Reports 13(4): 589-595

Johansson, S.; Wåhlander, K.; Larson, G.ör.; Ohlsson, L.; Larsson, M.; Eriksson, U.G. 2003: Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 14(7): 677-684

Vlasuk, G.P.; Bradbury, A.; Lopez-Kinninger, L.; Colón, S.; Bergum, P.W.; Maki, S.; Rote, W.E. 2003: Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. Thrombosis and Haemostasis 90(5): 803-812

Zhou, X.-f.; Macdiarmid, J.; Coburn, R.A.; Morris, M.E. 2005: Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. Biopharmaceutics and Drug Disposition 26(7): 279-285

Yang, Q.; Hu, Q. 2006: Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. European Journal of Drug Metabolism and Pharmacokinetics 31(1): 17-20

Armstrong, V.William.; Tenderich, G.; Shipkova, M.; Parsa, A.; Koerfer, R.; Schröder, H.; Oellerich, M. 2005: Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Therapeutic Drug Monitoring 27(3): 315-321

Zhang, J.H.; Zhu, J.B.; Chen, X.J.; Zhao, R.; Gang, Y.Y.; Wu, Z.H.; Cheng, K.; Xu, X.Y. 2001: Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir. European Journal of Drug Metabolism and Pharmacokinetics 26(3): 145-148

Zou-Jian-Jun; Xiao-Da-Wei; Zhu-Yu-Bing; Mo-Ling; Yu-Cui-Xia; Gu-Rong; Hu-Yun-Fang; Qian-Wei; Lou-Sheng 2005: Pharmacokinetics and bioavailability of two kinds of gliclazide sustained-release tablets following a single and multiple dose in healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 24(5): 337-341

Tian-Xin; Qiao-Hai-Ling; Guo-Yu-Zhong; Gao-Na; Jia-Lin-Jing; Zhang-Li-Rong 2006: Pharmacokinetics and bioavailability of two kinds of zidovudine capsules in Chinese healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 25(5): 321-325

Zhang-You-Jiu; Xu-Yu-Jie; Zhu-Ran; Hu-Ming-Jiang; Li-Jian-Xiang; Chen-Yue-Jin; Wang-Dao-Jin; Zhou-Li-Ren; Fan-Wo 2005: Pharmacokinetics and biodistribution of I-125 labeled rhTNT-IL2 in rats following a single intravenous injection. Zhongguo Yaolixue Tongbao 21(8): 1013-1016

Bibby, D.C.; Talmadge, J.E.; Dalal, M.K.; Kurz, S.G.; Chytil, K.M.; Barry, S.E.; Shand, D.G.; Steiert, M. 2005: Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. International Journal of Pharmaceutics 293(1-2): 281-290

Son, M-Kyung.; Choi, J-Hoon.; Lee, D-Sop.; Kim, C-Young.; Choi, S-Min.; Kang, K-Koo.; Byun, J.; Kim, D-Kyung.; Kim, B-Moon. 2005: Pharmacokinetics and biodistribution of a pGT2-VEGF plasmid DNA after administration in rats. Journal of Cardiovascular Pharmacology 46(5): 577-584

Han, L-Mei.; Guo, J.; Zhang, L-Jun.; Wang, Q-Song.; Fang, X-Ling. 2006: Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacologica Sinica 27(6): 747-753

Xie, H.; Audette, C.; Hoffee, M.; Lambert, J.M.; Blättler, W.A. 2003: Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. Journal of Pharmacology and Experimental Therapeutics 308(3): 1073-1082

Schluep, T.; Cheng, J.; Khin, K.T.; Davis, M.E. 2006: Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer ChemoTherapy and Pharmacology 57(5): 654-662

Harivardhan-Reddy, L.; Murthy, R.S.R. 2004: Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomedical Papers (Olomouc) 148(2): 161-166

Wang-Chang-Hong; Li-Hong; Chou-Gui-Xin; Cheng-Xue-Mei; Zhang-Fang; Wang-Zheng-Tao 2005: Pharmacokinetics and bioequiavalence assessment of Ginkgo biloba extract dropping pills and tablets. Zhongguo Xinyao yu Linchuang Zazhi 24(12): 946-950

Cho, H.Y.; Moon, J.D.; Lee, Y.B. 2004: Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers. International Journal of Clinical Pharmacology and Therapeutics 42(3): 174-180

Cho, H-Young.; Lee, Y-Bok. 2006: Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Archives of Pharmacal Research 29(6): 525-533

Wang-Run-Ling; Zhang-Qing-Wei; Yang-Jin-Rong; Fu-Jing-Wei; Zhang-Jun; Liu-Chang-Xiao 2006: Pharmacokinetics and bioequivalence of arginine ibuprofen syrup vs ibuprofen tablet in healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 25(1): 52-54

Wei, X.; Ding, L.; Gao, J-min.; Li, J.; Zhang, S-qiang.; Shen, J-ping.; Zhang, Y-di. 2004: Pharmacokinetics and bioequivalence of eperisone hydrochloride tablet in healthy subjects. Yao Xue Xue Bao 39(4): 309-311

Yun, M-Hyuk.; Kwon, J-Tack.; Kwon, K-il. 2005: Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. Archives of Pharmacal Research 28(4): 488-492

Hu-Yu-Rong; Qiao-Hai-Ling; Sun-Jian; Tian-Xin; Jia-Lin-Jing; Zhang-Li-Rong; Guo-Yu-Zhong; Gao-Na 2005: Pharmacokinetics and bioequivalence of rabeprazole capsule and tablet. Zhongguo Xinyao yu Linchuang Zazhi 24(5): 363-366

Wang-Peng; Hu-Guo-Xin; Qiu-Xiang-Jun; Chen-Bing-Bing; Xu-Peng; Dai-Zong-Shun 2006: Pharmacokinetics and bioequivalence of sertraline capsules and tablets. Zhongguo Xinyao yu Linchuang Zazhi 25(1): 39-42

Jiang, H.; Ding, L.; Yang, J.; Huang, X.; Liu, G-yu.; Zhang, Z-xing. 2004: Pharmacokinetics and bioequivalence of trimebutine dispersive tablet in healthy subjects. Yao Xue Xue Bao 39(3): 208-211

Ni-Li; Li-Jin-Heng; Cao-Xiao-Mei; Wang-Lin 2005: Pharmacokinetics and bioequivalence of two kinds of glucosamine indometacin enteric-coated tablets in Chinese male volunteers. Zhongguo Xinyao yu Linchuang Zazhi 24(2): 92-95

Yeh, G.-C.; Deng, S.-T.; Lo, C.-Y.; Chiang, P.-S.; Hsiong, C.-H. 2004: Pharmacokinetics and bioequivalence study of a generic desloratadine tablet formulation in healthy male volunteers. Arzneimittel-Forschung 54(3): 166-170

Wei-Min-Ji; Sun-Pei-Hong; Hou-Jie; Zhou-Ying; Zhao-Xia; Liu-Yu-Wang; Zhao-Dong-Fang; Zhang-Hui-Lin 2003: Pharmacokinetics and bioequivalence study of amoxycillin and clavulanic acid (7: 1) a new combination in healthy male volunteers. Zhongguo Kangshengsu Zazhi 28(11): 677-681

Lu-Yuan; Kang-Zi-Sheng; Wei-Min-Ji; Li-Man-Ning; Liu-Yan; Li-Tian-Yun; Xiao-Yong-Hong 2005: Pharmacokinetics and bioequivalence study of sustained-release tablets and conventional capsules of cefaclor in healthy volunteers. Zhongguo Kangshengsu Zazhi 30(9): 538-541

Lin, L.-Chwen; Tsai, T.-Hu 2006: Pharmacokinetics and brain distribution of unbound levamisole in the anesthetized rats using microdialysis and microbore column liquid chromatography. Analytica Chimica Acta 569(1-2): 145-150

Webster, R.; Edgington, A.; Phipps, J.; Walker, D. 2006: Pharmacokinetics and clearance processes of UK-279,276 (rNIF) in rat and dog: comparison with human data. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 36(4): 341-349

Fielding, C.L.; Brumbaugh, G.W.; Matthews, N.S.; Peck, K.E.; Roussel, A.J. 2006: Pharmacokinetics and clinical effects of a subanesthetic continuous rate infusion of ketamine in awake horses. American Journal of Veterinary Research 67(9): 1484-1490

Chan, A.L.; Juarez, M.; Allen, R.; Volz, W.; Albertson, T. 2005: Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatology Photoimmunology and Photomedicine 21(2): 72-78

Dadashzadeh, S.; Zarghi, A.; Ebrahimian, A.J. 2003: Pharmacokinetics and comparative bioavailability of two diltiazem tablet formulations in healthy volunteers. Daru 11(1): 14-18

Weinbauer, G.F.; Partsch, C.-J.; Zitzmann, M.; Schlatt, S.; Nieschlag, E. 2003: Pharmacokinetics and degree of aromatization rather than total dose of different preparations determine the effects of testosterone: a nonhuman primate study in Macaca fascicularis. Journal of Andrology 24(5): 765-774

Tachibana, S.; Fujimaki, Y.; Tachibana, M.; Tanaka, M.; Kurata, T.; Okazaki, O.; Sudo, K.-i. 2005: Pharmacokinetics and disposition of DY-9760e, a novel calmodulin antagonist, in rats and monkeys. Arzneimittel-Forschung 55(3): 135-144

Matsubara, Y.; Kanazawa, T.; Kojima, Y.; Abe, Y.; Kobayashi, K.; Kanbe, H.; Harada, H.; Momose, Y.; Terakado, S.; Adachi, Y.; Midgley, I. 2006: Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 126 Spec No.: 237-245

Mathews, J.M.; Etheridge, A.S.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T. 2005: Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals 33(10): 1555-1563

Gervasoni, M.; Pirola, R.; Pollera, C.; Villa, S.; Cignarella, G.; Mantegazza, P.; Poli, G.; Bareggi, S.R. 2004: Pharmacokinetics and distribution of sodium 3,4-diaminonaphthalene-1-sulfonate, a Congo Red derivative active in inhibiting PrP(res) replication. Journal of Pharmacy and Pharmacology 56(3): 323-328

Zhang, Y-long.; Xie, Y.; Wang, H-juan.; Hou, X-pu.; Liu, Y. 2005: Pharmacokinetics and distribution of superoxide dismutase liposomes in rats. Yao Xue Xue Bao 40(2): 173-177

Robatel, C.; Decosterd, L.A.; Biollaz, J.; Eckert, P.; Schaller, M.D.; Buclin, T. 2003: Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. Journal of Clinical Pharmacology 43(12): 1329-1340

Jain, S.K.; Punia, J.S. 2006: Pharmacokinetics and dosage regimen of furazolidone in poultry. Indian Veterinary Journal 83(7): 722-725

Mauras, N.; Lima, J.; Patel, D.; Rini, A.; di Salle, E.; Kwok, A.; Lippe, B. 2003: Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. Journal of Clinical Endocrinology and Metabolism 88(12): 5951-5956

Cullen, E.; Liao, J.; Lukacsko, P.; Niecestro, R.; Friedhoff, L. 2004: Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharmaceutics and Drug Disposition 25(6): 261-263

Adams, M.P.; Ahdieh, H. 2004: Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. PharmacoTherapy 24(4): 468-476

Hosoya, M.; Mori, S.; Tomoda, A.; Mori, K.; Sawaishi, Y.; Kimura, H.; Shigeta, S.; Suzuki, H. 2004: Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrobial Agents and ChemoTherapy 48(12): 4631-4635

Pereira, S.P.; Rowbotham, D.; Fitt, S.; Shearer, M.J.; Wendon, J.; Williams, R. 2005: Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. Journal of Hepatology 42(3): 365-370

Bianconi, M.; Ferraro, L.; Traina, G.C.; Zanoli, G.; Antonelli, T.; Guberti, A.; Ricci, R.; Massari, L. 2003: Pharmacokinetics and efficacy of ropivacaine continuous wound instillation after joint replacement surgery. British Journal of Anaesthesia 91(6): 830-835

Devoto, L.; Fuentes, A.; Palomino, A.; Espinoza, A.; Kohen, P.; Ranta, S.; von Hertzen, H. 2005: Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. Fertility and Sterility 84(1): 46-51

Cavaleri, M.; Riva, S.; Valagussa, A.; Guanci, M.; Colombo, L.; Dowell, J.; Stogniew, M. 2005: Pharmacokinetics and excretion of dalbavancin in the rat. Journal of Antimicrobial ChemoTherapy 55(Suppl 2): Ii31-Ii35

Kieback, A.G.; Iven, H.; Stolzenburg, K.; Eichner, E.; Ruckdeschel, W.; Baumann, G. 2003: Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. International Journal of Cardiology 91(2-3): 201-208

Jones, K.O.; Owusu-Ababio, G.; Vick, A.M.; Khan, M.A. 2006: Pharmacokinetics and hepatic extraction of recombinant human parathyroid hormone, hPTH (1-34), in rat, dog, and monkey. Journal of Pharmaceutical Sciences 95(11): 2499-2506

Canta, F.; Marrone, R.; Bonora, S.; D'Avolio, A.; Sciandra, M.; Sinicco, A.; De Rosa, F.G.; Di Perri, G. 2005: Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. Journal of Antimicrobial ChemoTherapy 55(2): 280-281

Melder, R.J.; Osborn, B.L.; Riccobene, T.; Kanakaraj, P.; Wei, P.; Chen, G.; Stolow, D.; Halpern, W.G.; Migone, T.-S.; Wang, Q.; Grzegorzewski, K.J.; Gallant, G. 2005: Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunology Immunotherapy: Cii 54(6): 535-547

Chu, D.-F.; Fu, X.-Q.; Liu, W.-H.; Liu, K.; Li, Y.-X. 2006: Pharmacokinetics and in vitro and in vivo correlation of huperzine a loaded poly(lactic-co-glycolic acid) microspheres in dogs. International Journal of Pharmaceutics 325(1-2): 116-123

Paalzow, L.K. 2004: Pharmacokinetics and individualized drug therapy. Anales de la Real Academia Nacional de Farmacia 70(3): 663-679

Ichimaru, N.; Takahara, S.; Moriyama, T.; Kondo, M.; Nonomura, N.; Tanaka, T.; Wang, J.D.; Imai, E.; Okuyama, A.; Kondo, Y. 2004: Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolaemic patients on maintenance haemodialysis. Journal of International Medical Research 32(1): 45-52

Leung, L.Y.; Lim, H-Keang.; Abell, M.W.; Zimmerman, J.J. 2006: Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. Therapeutic Drug Monitoring 28(1): 51-61

Lares-Asseff, I.; Juárez-Olguín, H.; Flores-Pérez, J.; Guillé-Pérez, A.; Vargas, A. 2004: Pharmacokinetics and metabolic rates of acetyl salicylic acid and its metabolites in an Otomi ethnic group of Mexico. Biological and Pharmaceutical Bulletin 27(5): 706-709

Bartels, M.J.; Hansen, S.C.; Thornton, C.M.; Brzak, K.A.; Mendrala, A.L.; Dietz, F.K.; Kastl, P.J. 2004: Pharmacokinetics and metabolism of 14C-1,3-dichloropropene in the Fischer 344 rat and the B6C3F1 mouse. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 34(2): 193-213

Strolin Benedetti, M.; Whomsley, R.; Nicolas, J.-M.; Young, C.; Baltes, E.èn. 2003: Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. European Journal of Clinical Pharmacology 59(8-9): 621-630

Morioka, Y.; Harada, M.; Imai, T.; Naito, S. 2003: Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 33(12): 1247-1260

Allan, G.A.; Gedge, J.I.; Nedderman, A.N.R.; Roffey, S.J.; Small, H.F.; Webster, R. 2006: Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 36(5): 399-418

Sobol, E.; Yagen, B.; Winkler, I.; Britzi, M.; Gibson, D.; Bialer, M. 2005: Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals 33(10): 1538-1546

Song, S.; Kwon, O.S.; Chung, Y.B. 2005: Pharmacokinetics and metabolism of acriflavine in rats following intravenous or intramuscular administration of AG60, a mixture of acriflavine and guanosine, a potential antitumour agent. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 35(7): 755-773

Gradolatto, A.él.; Basly, J.-P.; Berges, R.; Teyssier, C.; Chagnon, M.-C.; Siess, M.-H.él.én.; Canivenc-Lavier, M.-C. 2005: Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metabolism and Disposition: the Biological Fate of Chemicals 33(1): 49-54

Czejka, M.; Schueller, J.; Hauer, K.; Ostermann, E. 2005: Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer. Anticancer Research 25(4): 2985-2990

Mangold, J.B.; Gu, H.; Rodriguez, L.C.; Bonner, J.; Dickson, J.; Rordorf, C. 2004: Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition: the Biological Fate of Chemicals 32(5): 566-571

Komura, H.; Iwaki, M. 2005: Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. Journal of Pharmaceutical Sciences 94(2): 397-408

Tutka, P.; Mosiewicz, J.; Wielosz, M. 2005: Pharmacokinetics and metabolism of nicotine. Pharmacological Reports: Pr 57(2): 143-153

Ericsson, H.; Hamrén, B.; Bergstrand, S.; Elebring, M.; Fryklund, L.; Heijer, M.; Ohman, K.P. 2004: Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals 32(9): 923-929

Chen, X.; Cui, L.; Duan, X.; Ma, B.; Zhong, D. 2006: Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metabolism and Disposition: the Biological Fate of Chemicals 34(8): 1345-1352

Fernández-Varón, E.; Villamayor, L.; Escudero, E.; Espuny, A.; Cárceles, C.M. 2006: Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Veterinary Journal 172(2): 302-307

Jamois, C.; Comets, E.; Mentré, F.; Marion, S.; Farinotti, R.; Bonhomme-Faivre, L. 2005: Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. Cancer ChemoTherapy and Pharmacology 55(1): 61-71

Stass, H.; Rink, A.D.; Delesen, H.; Kubitza, D.; Vestweber, K.-H. 2006: Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. Journal of Antimicrobial ChemoTherapy 58(3): 693-696

Dilger, K.; Alberer, M.; Busch, A.; Enninger, A.; Behrens, R.; Koletzko, S.; Stern, M.; Beckmann, C.; Gleiter, C.H. 2006: Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Alimentary Pharmacology and Therapeutics 23(3): 387-396

Herman, G.A.; Bergman, A.; Liu, F.; Stevens, C.; Wang, A.Q.; Zeng, W.; Chen, L.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Meehan, A.G.; Lasseter, K.; Dilzer, S.; Blum, R.; Wagner, J.A. 2006: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. Journal of Clinical Pharmacology 46(8): 876-886

Tornatore, K.M.; Gilliland-Johnson, K.K.; Farooqui, M.; Reed, K.A.; Venuto, R.C. 2004: Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. Journal of Clinical Pharmacology 44(9): 1003-1011

Nugroho, A.K.; Romeijn, S.G.; Zwier, R.ël.; de Vries, J.B.; Dijkstra, D.; Wikström, H.åk.; Della-Pasqua, O.; Danhof, M.; Bouwstra, J.A. 2006: Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. Journal of Pharmaceutical Sciences 95(7): 1570-1585

Hebert, M.F.; Carr, D.B.; Anderson, G.D.; Blough, D.; Green, G.E.; Brateng, D.A.; Kantor, E.; Benedetti, T.J.; Easterling, T.R. 2004: Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. Journal of Clinical Pharmacology 45(1): 25-33

Mager, D.E.; Neuteboom, B.; Jusko, W.J. 2005: Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharmaceutical Research 22(1): 58-61

Imbeault, K.; Withington, D.E.; Varin, F. 2006: Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. Anesthesia and Analgesia 102(3): 738-743

Wermeling, D.P.; Record, K.A.; Kelly, T.H.; Archer, S.M.; Clinch, T.; Rudy, A.C. 2006: Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesthesia and Analgesia 103(2): 344-349 Table of Contents

Wong, S.L.; Lau, D.T-W.; Baughman, S.A.; Fotheringham, N.; Menchaca, D.; Garnick, M.B. 2004: Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. Journal of Clinical Pharmacology 44(5): 495-502

Washington, C.B.; Hou, S.Y.E.; Campanella, C.; Hughes, N.; Brown, S.; Berner, B. 2005: Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers. Journal of Clinical Pharmacology 45(11): 1236-1244

Cox, D.S.; Kleiman, N.S.; Boyle, D.A.; Aluri, J.; Parchman, L.G.; Holdbrook, F.; Fossler, M.J. 2004: Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. Journal of Clinical Pharmacology 44(9): 981-990

Suh, O.K.; Kim, S.H.; Lee, M.G. 2003: Pharmacokinetics and pharmacodynamics of azosemide. Biopharmaceutics and Drug Disposition 24(7): 275-297

Yun, H.-Y.; Yun, M.-H.; Kang, W.; Kwon, K.-I. 2005: Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. Journal of Clinical Pharmacy and Therapeutics 30(6): 541-547

Cole, A.; Mutlow, A.; Isaza, R.; Carpenter, J.W.; Koch, D.E.; Hunter, R.P.; Dresser, B.L. 2006: Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians 37(3): 318-326

Stegemann, M.R.; Sherington, J.; Blanchflower, S. 2006: Pharmacokinetics and pharmacodynamics of cefovecin in dogs. Journal of Veterinary Pharmacology and Therapeutics 29(6): 501-511

Sauermann, R.; Delle-Karth, G.; Marsik, C.; Steiner, I.; Zeitlinger, M.; Mayer-Helm, B.X.; Georgopoulos, A.; Müller, M.; Joukhadar, C. 2005: Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrobial Agents and ChemoTherapy 49(2): 650-655

Shi-Shao-Jun; Gu-Shi-Fen; Chen-Hui; Zeng-Fan-Dian 2005: Pharmacokinetics and pharmacodynamics of dauricine in beagle dogsl. Zhongguo Yaolixue Tongbao 21(4): 464-467

Rembratt, A.; Graugaard-Jensen, C.; Senderovitz, T.; Norgaard, J.Peter.; Djurhuus, J.Christian. 2004: Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. European Journal of Clinical Pharmacology 60(6): 397-402

Al Katheeri, N.A.; Wasfi, I.A.; Lambert, M.; Saeed, A. 2004: Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. Veterinary Research Communications 28(6): 525-542

Haas, C., E.; Nelsen, J., L.; Raghavendran, K.; Mihalko, W.; Beres, J.; Ma, Q.; Forrest, A. 2005: Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. Journal of Trauma Injury Infection and Critical Care 59(6): 1336-1343

Parra-Sanchez, A.; Lugo, J.; Boothe, D.M.; Gaughan, E.M.; Hanson, R.R.; Duran, S.; Belknap, J.K. 2006: Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses. American Journal of Veterinary Research 67(10): 1687-1695

Nix, D.E.; Majumdar, A.K.; DiNubile, M.J. 2004: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. Journal of Antimicrobial ChemoTherapy 53(Suppl 2): Ii23-Ii28

Fukasawa, T.; Yasui-Furukori, N.; Suzuki, A.; Inoue, Y.; Tateishi, T.; Otani, K. 2005: Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. European Journal of Clinical Pharmacology 61(11): 791-795

Komoriya, K.; Hoshide, S.; Takeda, K.; Kobayashi, H.; Kubo, J.; Tsuchimoto, M.; Nakachi, T.; Yamanaka, H.; Kamatani, N. 2004: Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides and Nucleic Acids 23(8-9): 1119-1122

Rook, E.J.; van Ree, J.M.; van den Brink, W.; Hillebrand, M.J.X.; Huitema, A.D.R.; Hendriks, V.M.; Beijnen, J.H. 2006: Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic and Clinical Pharmacology and Toxicology 98(1): 86-96

Fish, D.N.; Teitelbaum, I.; Abraham, E. 2005: Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrobial Agents and ChemoTherapy 49(6): 2421-2428

Wistuba, J.; Marc Luetjens, C.; Kamischke, A.; Gu, Y-Qun.; Schlatt, S.; Simoni, M.; Nieschlag, E. 2005: Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles. Journal of Medical Primatology 34(4): 178-187

Freeman, B.B.; Hinds, P.; Iacono, L.C.; Razzouk, B.I.; Burghen, E.; Stewart, C.F. 2006: Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Pediatric Blood and Cancer 47(5): 572-579

Sprandel, K.A.; Schriever, C.A.; Pendland, S.L.; Quinn, J.P.; Gotfried, M.H.; Hackett, S.; Graham, M.Beth.; Danziger, L.H.; Rodvold, K.A. 2004: Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. Antimicrobial Agents and ChemoTherapy 48(12): 4597-4605

Kim, Y.C.; Oh, E.Y.; Kim, S.H.; Lee, M.G. 2005: Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. Biopharmaceutics and Drug Disposition 26(8): 371-378

Poujol, S.; Bressolle, Fçoise.; Duffour, J.; Abderrahim, A.Gauthey.; Astre, Cécile.; Ychou, M.; Pinguet, Fédéric. 2006: Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer ChemoTherapy and Pharmacology 58(3): 292-305

Zhang-Yi; Bao-Yan-Yan; Ou-Min; Xia-Dong-Ya 2005: Pharmacokinetics and pharmacodynamics of levofloxacin in patients with respiratory tract infections using Bayesian forecasting. Zhongguo Kangshengsu Zazhi 30(11): 689-692

Stein, G.E.; Schooley, S.L.; Peloquin, C.A.; Kak, V.; Havlichek, D.H.; Citron, D.M.; Tyrrell, K.L.; Goldstein, E.J.C. 2005: Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Annals of PharmacoTherapy 39(3): 427-432

Ariano, R.E.; Nyhlén, A.; Donnelly, J.P.; Sitar, D.S.; Harding, G.K.M.; Zelenitsky, S.A. 2005: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Annals of PharmacoTherapy 39(1): 32-38

Smith, P.F.; Booker, B.M.; Creaven, P.; Perez, R.; Pendyala, L. 2003: Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. Journal of Clinical Pharmacology 43(12): 1324-1328

Hendrix, C.W.; Wakeford, J.; Wire, M.Beth.; Lou, Y.; Bigelow, G.E.; Martinez, E.; Christopher, J.; Fuchs, E.J.; Snidow, J.W. 2004: Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. PharmacoTherapy 24(9): 1110-1121

Scheidweiler, K.B.; Plessinger, M.A.; Shojaie, J.; Wood, R.W.; Kwong, T.C. 2003: Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. Journal of Pharmacology and Experimental Therapeutics 307(3): 1179-1187

Østergaard, D.; Viby-Mogensen, J.; Rasmussen, S.N.; Gätke, M.R.; Pedersen, N.A.; Skovgaard, L.T. 2003: Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). Acta Anaesthesiologica Scandinavica 47(10): 1219-1225

Østergaard, D.; Viby-Mogensen, Jørgen.; Rasmussen, Søren.N.; Gätke, M.R.; Varin, F. 2005: Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. Anesthesiology 102(6): 1124-1132

Ciraulo, D.A.; Hitzemann, R.J.; Somoza, E.; Knapp, C.M.; Rotrosen, J.; Sarid-Segal, O.; Ciraulo, A.M.; Greenblatt, D.J.; Chiang, C.N. 2006: Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. Journal of Clinical Pharmacology 46(2): 179-192

Mortensen, D.L.; Walicke, P.A.; Wang, X.; Kwon, P.; Kuebler, P.; Gottlieb, A.B.; Krueger, J.G.; Leonardi, C.; Miller, B.; Joshi, A. 2005: Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. Journal of Clinical Pharmacology 45(3): 286-298

Gao, W.; Kim, J.; Dalton, J.T. 2006: Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research 23(8): 1641-1658

Lalovic, B.; Kharasch, E.; Hoffer, C.; Risler, L.; Liu-Chen, L.-Y.; Shen, D.D. 2006: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology and Therapeutics 79(5): 461-479

Hedman, M.; Neuvonen, P.J.; Neuvonen, M.; Holmberg, C.; Antikainen, M. 2004: Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clinical Pharmacology and Therapeutics 75(1): 101-109

Minami, H.; Kawada, K.; Sasaki, Y.; Igarashi, T.; Saeki, T.; Tahara, M.; Itoh, K.; Fujii, H. 2006: Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Science 97(3): 235-241

Robertson, E.N.; Driessen, J.J.; Booij, L.H.D.J. 2005: Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. European Journal of Anaesthesiology 22(1): 4-10

Marzo, A.; Dal Bo, L.; Monti, N.C.; Crivelli, F.; Ismaili, S.; Caccia, C.; Cattaneo, C.; Fariello, R.G. 2004: Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacological Research 50(1): 77-85

Herman, G.A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A.Q.; Zeng, W.; Musson, D.; Winchell, G.; Davies, M.J.; Ramael, S.; Gottesdiener, K.M.; Wagner, J.A. 2005: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology and Therapeutics 78(6): 675-688

Guth, B.D.; Narjes, H.; Schubert, H.-D.; Tanswell, P.; Riedel, A.; Nehmiz, G. 2004: Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. British Journal of Clinical Pharmacology 58(1): 40-51

Agwuh, K.N.; MacGowan, A. 2006: Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. Journal of Antimicrobial ChemoTherapy 58(2): 256-265

Azizi, M.; Bissery, A.; Peyrard, S.év.; Guyene, T.T.; Ozoux, M.-L.; Floch, A.; Ménard, J.ël. 2006: Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clinical Pharmacology and Therapeutics 79(1): 49-61

Modi, N.B.; Kell, S.; Simon, M.; Vargas, R. 2005: Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. Journal of Clinical Pharmacology 45(8): 919-926

Fujisaka, Y.; Tamura, T.; Ohe, Y.; Kunitoh, H.; Sekine, I.; Yamamoto, N.; Nokihara, H.; Horiike, A.; Kodama, T.; Saijo, N. 2006: Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Japanese Journal of Clinical Oncology 36(8): 477-482

Arafat, T.; Awad, R.; Hamad, M.; Azzam, R.; Al-Nasan, A.; Jehanli, A.; Matalka, K. 2005: Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. Journal of Clinical Pharmacy and Therapeutics 30(4): 319-328

Sharma, S.; Dube, A.; Bose, B.; Gupta, P.K. 2005: Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles. Cancer ChemoTherapy and Pharmacology 57(4): 500-506

Cendros, J.M.; Peraire, Cón.; Trocóniz, Iñaki.Fernández.; Obach, R. 2005: Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism, Clinical and Experimental 54(10): 1276-1281

Zhang Jin; Chen Shao Hang 2004: Pharmacokinetics and reasonable clinical application of angiotensin II receptor antagonist. Zhongguo Xinyao yu Linchuang Zazhi 23(2): 111-115

Shentu, J.-Zhong; Ni, L.-Qiang; Chen, Z.-Gen; Zhang, X.; Wu, L.-Hua; Wang, T.; Lu, X.-Yang 2004: Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body. Zhongguo Xinyao yu Linchuang Zazhi 23(11): 742-744

H.H.i Xia; Zhou Yuan Da; Wang Ning; Chen Feng Jie 2004: Pharmacokinetics and relative bioavailability of domestic vs imported tizanidine tablets in human body. Zhongguo Xinyao yu Linchuang Zazhi 23(7): 427-429

Zhu-Nan-Ping; Zhang-Bi-Kui; Zhu-Yun-Gui; Peng-Wen-Xing; Li-Kun-Yan; Li-Huan-De 2005: Pharmacokinetics and relative bioavailability of gemfibrozil by HPLC determined in human being. Zhongguo Xinyao yu Linchuang Zazhi 24(1): 29-32

Agersø, H.; Seiding Larsen, L.; Riis, A.; Lövgren, U.; Karlsson, M.O.; Senderovitz, T. 2004: Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. British Journal of Clinical Pharmacology 58(4): 352-358

Hedman, M.; Antikainen, M.; Holmberg, C.; Neuvonen, M.; Eichelbaum, M.; Kivistö, K.T.; Neuvonen, P.J.; Niemi, M. 2006: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British Journal of Clinical Pharmacology 61(6): 706-715

Wire, M.Beth.; Ballow, C.; Preston, S.L.; Hendrix, C.W.; Piliero, P.J.; Lou, Y.; Stein, D.S. 2004: Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. Aids 18(6): 897-907

Wieder, R.; Novick, S.C.; Hollis, B.W.; Bryan, M.; Chanel, S.M.; Owusu, K.; Camastra, D.; Saunders, T.; Pliner, L.; Harrison, J.; Bonate, P.; Williams, T.; Soignet, S. 2003: Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Investigational New Drugs 21(4): 445-452

Thürmann, P.A.; Szymanski, J.; Haffner, S.; Tenter, U.; Grieger, F.; Sonnenburg, C. 2006: Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. European Journal of Clinical Pharmacology 62(7): 511-512

Harrison, L.I.; Skinner, S.L.; Marbury, T.C.; Owens, M.L.; Kurup, S.; McKane, S.; Greene, R.J. 2004: Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Archives of Dermatological Research 296(1): 6-11

Fauser, S.; Kalbacher, H.; Alteheld, N.; Koizumi, K.; Krohne, T.U.; Joussen, A.M. 2004: Pharmacokinetics and safety of intravitreally delivered etanercept. Graefe's Archive for Clinical and Experimental Ophthalmology 242(7): 582-586

Knorr, B.; Maganti, L.; Ramakrishnan, R.; Tozzi, C.A.; Migoya, E.; Kearns, G. 2006: Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. Journal of Clinical Pharmacology 46(6): 620-627

Huber, M.; Bolbrinker, J.; Kreutz, R. 2006: Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Clinical and Experimental Hypertension 28(7): 631-643

McEwen, J.; Salva, M.; Jansat, J.M.; Cabarrocas, X. 2004: Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. Biopharmaceutics and Drug Disposition 25(7): 303-311

Smulders, R.A.; Krauwinkel, W.J.; Swart, P.J.; Huang, M. 2004: Pharmacokinetics and safety of solifenacin succinate in healthy young men. Journal of Clinical Pharmacology 44(9): 1023-1033

Wade, N.A.; Unadkat, J.D.; Huang, S.; Shapiro, D.E.; Mathias, A.; Yasin, S.; Ciupak, G.; Watts, D.H.; Delke, I.; Rathore, M.; Hitti, J.; Frenkel, L.; Samelson, R.; Smith, M.E.; Mofenson, L.; Burchett, S.K. 2004: Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. Journal of Infectious Diseases 190(12): 2167-2174

Bapst, J.L.; Ermer, J.C.; Ferron, G.M.; Foss, D.; Orczyk, G.P. 2006: Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception 74(5): 414-418

Baker, J.F.; Kratz, L.C.; Stevens, G.R.; Wible, J.H. 2004: Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects. Investigative Radiology 39(6): 334-339

Shi, J.; Montay, G.; Chapel, S.; Hardy, P.; Barrett, J.S.; Sack, M.; Marbury, T.; Swan, S.K.; Vargas, R.; Leclerc, V.; Leroy, B.; Bhargava, V.O. 2004: Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. Journal of Clinical Pharmacology 44(3): 234-244

Lin, C.-C.; Philips, L.; Xu, C.; Yeh, L.-T. 2004: Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. Journal of Clinical Pharmacology 44(3): 265-275

Dunbar, G.; Demazières, A.; Monreal, A.; Cisterni, C.; Metzger, D.; Kuchibhatla, R.; Luthringer, R. 2006: Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. Journal of Clinical Pharmacology 46(7): 715-726

Adkison, K.K.; Shachoy-Clark, A.; Fang, L.; Lou, Y.; O'Mara, K.; Berrey, M.M.; Piscitelli, S.C. 2005: Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrobial Agents and ChemoTherapy 49(7): 2802-2806

Hua, J.; Sheng, Y.; Olin, M.; Pero, R.; Edvardsen, K. 2004: Pharmacokinetics and splenic accumulation of N-acetylamino-3-chloro-N-(2-diethylamino-ethyl) benzamide after a single administration to rats. Biopharmaceutics and Drug Disposition 25(7): 313-322

Valdivia, A.; Pérez, Y.; Gómez, L.; Ramírez, H.L.; Schacht, E.H.; Villalonga, R. 2006: Pharmacokinetics and stability properties of catalase modified with water-soluble polysaccharides. Archiv der Pharmazie 339(7): 372-377

Rad, M.; Hümpel, M.; Schaefer, O.; Schoemaker, R.C.; Schleuning, W.-D.; Cohen, A.F.; Burggraaf, J. 2006: Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. British Journal of Clinical Pharmacology 62(3): 288-296

Tang, J.; Yang, X.-Le; Zheng, Z.-Lin; Yu, W.-Juan; Hu, K.; Yu, H.-Juan 2006: Pharmacokinetics and the active metabolite of enrofloxacin in Chinese mitten-handed crab (Eriocheir sinensis). Aquaculture 260(1-4): 69-76

Höcht, C.; Opezzo, J.A.W.; Taira, C.A. 2004: Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. Pharmacology 70(1): 23-30

Bae, S.K.; Lee, S.J.; Kim, T.; Kim, J.W.; Lee, I.; Kim, S.G.; Lee, M.G. 2006: Pharmacokinetics and therapeutic effects of oltipraz after consecutive or intermittent oral administration in rats with liver cirrhosis induced by dimethylnitrosamine. Journal of Pharmaceutical Sciences 95(5): 985-997

Jin, Y.; Li, J.; Rong, L.-F.; Lü, X.-W.; Huang, Y.; Xu, S.-Y. 2005: Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. Acta Pharmacologica Sinica 26(2): 250-256

Wang, C-Hong.; Wang, Z-Tao.; Bligh, S.W.Annie.; White, K.N.; White, C.J.Branford. 2004: Pharmacokinetics and tissue distribution of gentiopicroside following oral and intravenous administration in mice. European Journal of Drug Metabolism and Pharmacokinetics 29(3): 199-203

Tasso, L.; Neves, G.; Menegatti, R.; Fraga, C.A.M.; Barreiro, E.; Eifler-Lima, V.; Rates, S.M.K.; Costa, T.D. 2005: Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 26(2): 194-202

Teng, X.W.; Davies, N.M.; Fukuda, C.; Good, R.L.; Fariss, M.W. 2005: Pharmacokinetics and tissue distribution of d-alpha-tocopheryl succinate formulations following intravenous administration in the rat. Biopharmaceutics and Drug Disposition 26(5): 195-203

Reddy, P.Ram.; Venkateswarlu, V. 2005: Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. Journal of Drug Targeting 13(10): 543-553

Patlolla, R.R.; Vobalaboina, V. 2005: Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. Journal of Pharmaceutical Sciences 94(2): 437-445

Mohamed, F.; Marchettini, P.; Stuart, O.A.; Sugarbaker, P.H. 2003: Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer ChemoTherapy and Pharmacology 52(5): 405-410

Sova, P.; Chladek, J.; Zak, F.; Mistr, A.; Kroutil, A.; Semerad, M.; Slovak, Z. 2005: Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 ((OC-6-43)bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)). International Journal of Pharmaceutics (Kidlington) 288(1): 123-129

Meririnne, E.; Ellermaa, S.; Kankaanpää, A.; Bardy, A.; Seppälä, T. 2004: Pharmacokinetics and tissue distribution of the stereoisomers of 4-methylaminorex in the rat. Journal of Pharmacology and Experimental Therapeutics 309(3): 1198-1205

Deguchi, T.; Nakamura, M.; Tsutsumi, Y.; Suenaga, A.; Otagiri, M. 2003: Pharmacokinetics and tissue distribution of uraemic indoxyl sulphate in rats. Biopharmaceutics and Drug Disposition 24(8): 345-355

Jin, S.X.; Bi, D.Z.; Wang, J.; Wang, Y.Z.; Hu, H.G.; Deng, Y.H. 2005: Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Die Pharmazie 60(11): 840-843

Hori, T.; Nakano, M.; Kimura, Y.; Murakami, K. 2006: Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20(1): 91-96

Wang, X.; Feng, Y.; Ke, T.; Schabel, M.; Lu, Z-Rong. 2005: Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. Pharmaceutical Research 22(4): 596-602

Escudero, E.; Fernández-Varón, E.; Marín, P.; Espuny, A.; Nájera, M.D.; Cárceles, C.M. 2006: Pharmacokinetics and tissue tolerance of azithromycin after intramuscular administration to rabbits. Research in Veterinary Science 81(3): 366-372

Ross, R.J.M.; Jabbar, A.; Jones, T.H.; Roberts, B.; Dunkley, K.; Hall, J.; Long, A.; Levine, H.; Cullen, D.R. 2004: Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. European Journal of Endocrinology 150(1): 57-63

Lennernäs, B.; Hedner, T.; Holmberg, M.; Bredenberg, S.; Nyström, C.; Lennernäs, H. 2005: Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. British Journal of Clinical Pharmacology 59(2): 249-253

Sidhu, J.; Job, S.; Bullman, J.; Francis, E.; Abbott, R.; Ascher, J.; Theis, J.G.W. 2006: Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. British Journal of Clinical Pharmacology 61(4): 420-426

Eerdekens, M.ël.; Van Hove, I.; Remmerie, B.; Mannaert, E. 2004: Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research 70(1): 91-100

Tran, A.; Jullien, V.; Alexandre, J.; Rey, E.; Rabillon, F.; Girre, V.; Dieras, V.; Pons, G.; Goldwasser, F.; Tréluyer, J.M. 2006: Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical Pharmacology and Therapeutics 79(6): 570-580

Moisés, E.C.D.; de Barros Duarte, L.; de Carvalho Cavalli, R.; Lanchote, V.L.úc.; Duarte, G.; da Cunha, S.ér.P. 2005: Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. European Journal of Clinical Pharmacology 61(7): 517-522

Cavalli, R.d.C.; Lanchote, V.L.úc.; Duarte, G.; Dantas, E.C.M.és.; de Prado, M.F.M.; de Duarte, L.B.; da Cunha, S.ér.P. 2004: Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. European Journal of Clinical Pharmacology 60(8): 569-574

Chen, X.; Park, R.; Shahinian, A.H.; Bading, J.R.; Conti, P.S. 2004: Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nuclear Medicine and Biology 31(1): 11-19

Bedikian, A.Y.; Vardeleon, A.; Smith, T.; Campbell, S.; Namdari, R. 2006: Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. Journal of Clinical Pharmacology 46(7): 727-737

Ramanathan-Girish, S.; McColm, J.; Clements, J.M.; Taupin, P.; Barrowcliffe, S.; Hevizi, J.; Safrin, S.; Moore, C.; Patou, G.; Moser, H.; Gadd, A.; Hoch, U.; Jiang, V.; Lofland, D.; Johnson, K.W. 2004: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrobial Agents and ChemoTherapy 48(12): 4835-4842

He, J.; Liu, G.; Zhang, S.; Rusckowski, M.; Hnatowich, D.J. 2003: Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting. Cancer BioTherapy and Radiopharmaceuticals 18(6): 941-947

Rubins, A.; Gutmane, R.; Valdmane, N.; Stevenson, P.; Foster, C.; Undre, N. 2005: Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. Journal of Investigative Dermatology 125(1): 68-71

Ala-Kokko, T.I.; Räihä, E.; Karinen, J.; Kiviluoma, K.; Alahuhta, S. 2005: Pharmacokinetics of 0.5% levobupivacaine following ilioinguinal-iliohypogastric nerve blockade in children. Acta Anaesthesiologica Scandinavica 49(3): 397-400

Peyrot, F.; Grillon, C.; Vergely, C.; Rochette, L.; Ducrocq, C. 2005: Pharmacokinetics of 1-nitrosomelatonin and detection by EPR using iron dithiocarbamate complex in mice. Biochemical Journal 387(Part 2): 473-478

Leminen, R.; Ranta, S.; von Hertzen, H.; Oehler, J.; Heikinheimo, O. 2003: Pharmacokinetics of 10 mg of mifepristone. Contraception 68(6): 427-429

Yoo, B-Im.; Ahan, K.Bok.; Kang, M.Hee.; Kwon, O-Seung.; Hong, Y-Soo.; Lee, J.Joon.; Lee, H.Sub.; Ryu, J.Su.; Kim, T.Yong.; Moon, D-Cheul.; Song, S.; Chung, Y.Bok. 2005: Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats. Archives of Pharmacal Research 28(4): 476-482

Muindi, J.R.; Modzelewski, R.A.; Peng, Y.; Trump, D.L.; Johnson, C.S. 2004: Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 66(1): 62-66

Sadahiro, S.; Suzuki, T.; Ishikawa, K.; Tanaka, Y.; Masuda, T.; Nakamura, T.; Yasuda, S.; Makuuchi, H.; Murayama, C. 2003: Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. Japanese Journal of Clinical Oncology 33(8): 377-381

Choi, Y.H.; Lee, A.K.; Bae, S.K.; Kim, S.O.; Lee, M.G. 2005: Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharmaceutics and Drug Disposition 26(3): 93-98

Hitzman, C.J.; Wattenberg, L.W.; Wiedmann, T.S. 2006: Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. Journal of Pharmaceutical Sciences 95(6): 1196-1211

Derijks, L.J.J.; Gilissen, L.P.L.; Engels, L.G.J.B.; Bos, L.P.; Bus, P.J.; Lohman, J.J.H.M.; Curvers, W.L.; Van Deventer, S.J.H.; Hommes, D.W.; Hooymans, P.M. 2004: Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Therapeutic Drug Monitoring 26(3): 311-318

Derijks, L.J.J.; Gilissen, L.P.L.; Engels, L.G.J.B.; Bos, L.P.; Bus, P.J.; Lohman, J.J.H.M.; van Deventer, S.J.H.; Hommes, D.W.; Hooymans, P.M. 2006: Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Therapeutic Drug Monitoring 28(1): 45-50

Edwards, D.J.; Chugani, D.C.; Chugani, H.T.; Chehab, J.; Malian, M.; Aranda, J.V. 2006: Pharmacokinetics of buspirone in autistic children. Journal of Clinical Pharmacology 46(5): 508-514

Guan, L.; Feng, Y.; Ji, M.; Dai, D.-z. 2006: Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice. Acta Pharmacologica Sinica 27(3): 367-371

Chung, H.J.; Choi, Y.H.; Choi, H.D.; Jang, J.M.; Shim, H.J.; Yoo, M.; Kwon, J.W.; Lee, M.G. 2006: Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 27(4): 363-374

Bae, S.K.; Chung, W-Suk.; Kim, E.J.; Rhee, J.K.; Kwon, J.W.; Kim, W.B.; Lee, M.G. 2004: Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrobial Agents and ChemoTherapy 48(2): 659-662

Lee, J.H.; Kim, Y.C.; Kwon, J.W.; Kim, W.B.; Lee, M.G. 2005: Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. International Journal of Pharmaceutics 296(1-2): 94-102

Shim, H.J.; Kim, Y.C.; Park, K.J.; Kim, D.S.; Kwon, J.W.; Kim, W.B.; Lee, M.G. 2003: Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. Journal of Pharmaceutical Sciences 92(11): 2185-2195

Masubuchi, N. 2004: Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. Die Pharmazie 59(5): 374-377

Phan, G.; Herbet, A.; Cholet, S.; Benech, H.; Deverre, J-Robert.; Fattal, E. 2005: Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation. Journal of controlled release: official journal of the Controlled Release Society 110(1): 177-188

Liang, E.; Wong, Y.N.; Allen, I.; Kao, R.; Marino, M.; DiLea, C. 2003: Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function. Journal of Clinical Pharmacology 43(12): 1361-1369

Song, H.-f.; Liu, X.-w.; Zhang, H.-n.; Zhu, B.-z.; Yuan, S.-j.; Liu, S.-y.; Tang, Z.-m. 2005: Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacologica Sinica 26(1): 124-128

Tak, P.P.; Bacchi, M.; Bertolino, M. 2006: Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. European Journal of Drug Metabolism and Pharmacokinetics 31(2): 109-116

Murata, M. 2006: Pharmacokinetics of L-dopa - Special reference to food and aging. Journal of Neurology 253(Suppl 3): 47-52

Zhang, J.; Qu, F.-r.; Nakatsuka, A.; Nomura, T.; Nagai, M.; Nomoto, M. 2003: Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Research 993(1-2): 54-58

Emmons, G.T.; Argenti, R.; Martin, L.L.; Martin, N.E.; Jensen, B.K. 2004: Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers. Journal of Clinical Pharmacology 44(8): 901-905

Lu, H.; Chan, K.K. 2006: Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat. Cancer ChemoTherapy and Pharmacology 58(4): 532-539

Soldini, D.; Zwahlen, H.; Gabutti, L.; Marzo, A.; Marone, C. 2005: Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. European Journal of Clinical Pharmacology 60(12): 859-864

Kwon, O.-S.; Chung, U.T.; Chung, Y.B. 2004: Pharmacokinetics of PEG-hemoglobin SB1, a hemoglobin-based oxygen carrier, after its intravenous administration in beagle dogs. Archives of Pharmacal Research 27(2): 259-264

Melo, C.A.S.; Kurachi, C.; Grecco, C.; Sibata, C.H.; Castro-e-Silva, O.; Bagnato, V.S. 2004: Pharmacokinetics of Photogem using fluorescence monitoring in Wistar rats. Journal of Photochemistry and Photobiology. B Biology 73(3): 183-188

White, M.; de Graaff, P.; Renshof, B.; van Kan, E.; Dzoljic, M. 2006: Pharmacokinetics of S(+) ketamine derived from target controlled infusion. British Journal of Anaesthesia 96(3): 330-334

Oshima, T.; Yamada, R.; Hatori, S.; Kunisaki, C.; Imada, T. 2006: Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. Oncology Reports 16(2): 361-366

Takizawa, Y.; Morita, T.; Fujitsuka, N.; Kido, A.; Shindou, S.; Tomisawa, H.; Kase, Y.; Takeda, S.; Aburada, M.; Miyamoto, Kńtchi. 2005: Pharmacokinetics of TJ-8117(Onpi-to), a drug for renal failure (II): effects of food, repeated administration and renal failure to plasma concentration of [3H]-(-)epicatechin 3-O-gallate in rats. European Journal of Drug Metabolism and Pharmacokinetics 30(3): 175-180

Morris, T.A.; Jacobson, A.; Marsh, J.J.; Lane, J.R. 2005: Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thrombosis Research 115(1-2): 45-51

Mano, Y.; Usui, T.; Kamimura, H. 2004: Pharmacokinetics of YM466, a new factor Xa inhibitor, in rats and dogs. European Journal of Drug Metabolism and Pharmacokinetics 29(1): 7-13

Liu-De-Sheng; Meng-Zhi-Yun; Zhao-Gui-Sen; Dou-Gui-Fang; Zhang-Ya-Dong 2005: Pharmacokinetics of sifuvirtide in rats. Zhongguo Yaolixue Yu Dulixue Zazhi 19(4): 296-299

Pérez-Guillé, B.; Sumano, L.H.; Villegas-Alvarez, F.; Soriano-Rosales, R.; González-Zamora, J.F.; Jiménez-Bravo-Luna, M.; Carmona-Mancilla, A.; Ocampo, C.L. 2004: Pharmacokinetics of a cephalone (CQ-M-EPCA) in rats after oral, intraduodenal and intravenous administration. International Journal of Pharmaceutics 282(1-2): 87-94

Paek, I.B.; Moon, Y.; Kim, J.; Ji, H.Y.; Kim, S.A.; Sohn, D.H.; Kim, J.B.; Lee, H.S. 2006: Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharmaceutics and Drug Disposition 27(1): 39-45

Shermatova, L.; Aliev, H.U.; Nazarov, E.A.; Khuzhaev, S.; Ganiev, D.A.; Sultanov, A.; Markelova, E.A.; Akobirkhodzhaeva, G.S. 2006: Pharmacokinetics of a new Co-101 preparation studied by radionuclide method. Khimiko Farmatsevticheskii Zhurnal 40(9): 5-6

Wu, P.-Chu; Huang, Y.-Bin; Chang, C.-Kai; Chen, Y.-Long; Tzeng, C.-Chyi; Tsai, Y.-Hung 2005: Pharmacokinetics of a new antitumor agent, 1-quinolin-4-ylamino)phenyl-ethanoe-O-methyl-oxime, in rat using a high performance liquid chromatography method. Journal of Food and Drug Analysis 13(1): 38-42

Antonijoan, R.M.; Barbanoj, M.J.; Cordero, J.A.; Peraire, C.; Obach, R.; Vallès, J.; Chérif-Cheikh, R.; Torres, M.-L.; Bismuth, F.; Montes, M. 2004: Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology 56(4): 471-476

Cainazzo, M.M.; Pinetti, D.; Savino, G.; Bartiromo, M.; Forgione, A.; Bertolini, A. 2005: Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. Drugs under Experimental and Clinical Research 31(3): 115-121

Lee, S.; Kim, S.K.; Lee, D.Y.; Chae, S.Y.; Byun, Y. 2006: Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats. Antimicrobial Agents and ChemoTherapy 50(5): 1869-1871

Dockens, R.C.; Salazar, D.E.; Fulmor, I.Edgar.; Wehling, M.; Arnold, M.E.; Croop, R. 2006: Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. Journal of Clinical Pharmacology 46(11): 1308-1312

Kim, S.J.; Lee, H.I.; Ji, H.Y.; Moon, Y.; Paek, I.B.; Lee, S.; Yi, K.Y.; Yoo, S.D.; Lee, H.S. 2005: Pharmacokinetics of a novel antiangiogenic agent KR-31831 in rats. Biopharmaceutics and Drug Disposition 26(1): 21-26

Li-Dong-Liang; Lu-Lian-Huang; Lin-Jin-Juan; Wei-Li-Giang; Lin-Zhen-Xing 2004: Pharmacokinetics of a novel c-Myc antisense phosphorothioate oligodeoxynucleotide in mice. Zhongguo Xinyao yu Linchuang Zazhi 23(3): 136-138

Shin, B.S.; Chang, H.S.; Park, E.H.; Yoon, C.H.; Kim, H.Y.; Kim, J.; Ryu, J.K.; Zee, O.P.; Lee, K.C.; Cao, D.; Yoo, S.D. 2006: Pharmacokinetics of a novel histone deacetylase inhibitor, apicidin, in rats. Biopharmaceutics and Drug Disposition 27(2): 69-75

Fiala, C.; Aronsson, A.; Granath, F.; Stephansson, O.; Seyberth, H.W.; Watzer, B.; Gemzell-Danielsson, K. 2005: Pharmacokinetics of a novel oral slow-release form of misoprostol. Human Reproduction 20(12): 3414-3418

Shangguan, W.Ning.; Lian, Q.; Aarons, L.; Matthews, I.; Wang, Z.; Chen, X.; Freemantle, N.; Smith, F.Gao. 2006: Pharmacokinetics of a single bolus of propofol in chinese children of different ages. Anesthesiology 104(1): 27-32

Singh, A.B.; Lee, M.L.; Sinha-Hikim, I.; Kushnir, M.; Meikle, W.; Rockwood, A.; Afework, S.; Bhasin, S. 2006: Pharmacokinetics of a testosterone gel in healthy postmenopausal women. Journal of Clinical Endocrinology and Metabolism 91(1): 136-144

Matsumoto, K.-I.; English, S.; Yoo, J.; Yamada, K.-I.; Devasahayam, N.; Cook, J.A.; Mitchell, J.B.; Subramanian, S.; Krishna, M.C. 2004: Pharmacokinetics of a triarylmethyl-type paramagnetic spin probe used in EPR oximetry. Magnetic Resonance in Medicine 52(4): 885-892

Geary, R.S.; Yu, R.Z.; Watanabe, T.; Henry, S.P.; Hardee, G.E.; Chappell, A.; Matson, J.; Sasmor, H.; Cummins, L.; Levin, A.A. 2003: Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metabolism and Disposition: the Biological Fate of Chemicals 31(11): 1419-1428

Bentz, B.G.; Maxwell, L.K.; Erkert, R.S.; Royer, C.M.; Davis, M.S.; MacAllister, C.G.; Clarke, C.R. 2006: Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. Journal of Veterinary Internal Medicine 20(3): 589-594

Stagni, G.; Ali, M.E.; Weng, D. 2004: Pharmacokinetics of acyclovir in rabbit skin after I.v.-bolus, ointment, and iontophoretic administrations. International Journal of Pharmaceutics 274(1-2): 201-211

Meng Zhi Yun; Dou Gui Fang; Sun Wen Zhong; Zhu Xiao Xia; Zhang Liang; Tang Zhong Ming 2003: Pharmacokinetics of adefovir dipivoxil in monkeys and its distribution in rat tissues. Zhongguo Yaolixue Yu Dulixue Zazhi 17(6): 447-450

La Porte, C.J.L.; Colbers, E.P.H.; Bertz, R.; Voncken, D.S.; Wikstrom, K.; Boeree, M.J.; Koopmans, P.P.; Hekster, Y.A.; Burger, D.M. 2004: Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrobial Agents and ChemoTherapy 48(5): 1553-1560

Teichert, J.; Tuemmers, T.; Achenbach, H.; Preiss, C.; Hermann, R.; Ruus, P.; Preiss, R. 2005: Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. Journal of Clinical Pharmacology 45(3): 313-328

Hu, K.; Morris, M.E. 2005: Pharmacokinetics of alpha-naphthyl isothiocyanate in rats. Journal of Pharmaceutical Sciences 94(11): 2441-2451

Guffanti, M.; De Pascalis, C.Raffaella.; Seminari, E.; Fusetti, G.; Gianotti, N.; Bassetti, D.; Galli, A.; Castagna, A.; Lazzarin, A. 2003: Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. Aids 17(18): 2669-2671

Matsunaga, Y.; Hamada, A.; Okamoto, I.; Sasaki, J-ichiro.; Moriyama, E.; Kishi, H.; Matsumoto, M.; Hira, A.; Watanabe, H.; Saito, H. 2006: Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Therapeutic Drug Monitoring 28(1): 76-82

Löbenberg, R.; Kim, J.S.; Amidon, G.L. 2005: Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 60(1): 17-23

Blase, E.; Taylor, K.; Gao, H.-Y.; Wintle, M.; Fineman, M. 2005: Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. Journal of Clinical Pharmacology 45(5): 570-577

Frank, T.; Janssen, M.; Netzel, M.; Strass, G.; Kler, A.; Kriesl, E.; Bitsch, I. 2005: Pharmacokinetics of anthocyanidin-3-glycosides following consumption of Hibiscus sabdariffa L. extract. Journal of Clinical Pharmacology 45(2): 203-210

Ma-Yue-Ming; Zhao-Yang; Xie-Hua; Wang-Tian-Ming; Zhu-Shi-Min; Wu-Yao-Ping; Zhang-Ning 2005: Pharmacokinetics of anthraquinones in rats after intragastric gavage of Taohechengqi decoction. Zhongguo Yaolixue Tongbao 21(10): 1267-1270

Oo, C.; Hill, G.; Dorr, A.; Liu, B.; Boellner, S.; Ward, P. 2003: Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. European Journal of Clinical Pharmacology 59(5-6): 411-415

Pacifici, G.M. 2005: Pharmacokinetics of antivirals in neonate. Early Human Development 81(9): 773-780

Majumdar, A.K.; Howard, L.; Goldberg, M.R.; Hickey, L.; Constanzer, M.; Rothenberg, P.L.; Crumley, T.M.; Panebianco, D.; Bradstreet, T.E.; Bergman, A.J.; Waldman, S.A.; Greenberg, H.E.; Butler, K.; Knops, A.; De Lepeleire, I.; Michiels, N.; Petty, K.J. 2006: Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of Clinical Pharmacology 46(3): 291-300

Citrome, L.; Josiassen, R.; Bark, N.; Salazar, D.E.; Mallikaarjun, S. 2005: Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Journal of Clinical Pharmacology 45(1): 89-93

Grossmann, M.; Sattler, G.; Pistner, H.; Oertel, R.; Richter, K.; Schinzel, S.; Jacobs, L.-D. 2004: Pharmacokinetics of articaine hydrochloride in tumescent local anesthesia for liposuction. Journal of Clinical Pharmacology 44(11): 1282-1289

Ma-Yue-Ming; Xie-Hua; Zhu-Shi-Min; Wu-Yao-Ping; Wu-Da-Zheng; Hu-Zhi-Bi 2004: Pharmacokinetics of astragaloside IV in rabbits and its excretion in rats. Zhongguo Xinyao yu Linchuang Zazhi 23(9): 563-567

Wilms, E.B.; Touw, D.J.; Heijerman, H.G.M. 2006: Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Therapeutic Drug Monitoring 28(2): 219-225

Codacci-Pisanelli, G.; Pinedo, H.M.; Lankelma, J.; Van Groeningen, C.J.; Van Kuilenburg, A.B.P.; Van Gennip, A.H.; Peters, G.J. 2005: Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. Journal of ChemoTherapy 17(3): 315-320

Lo, W-Li.; Guo, J-Xin.; Ping, Q-Neng.; Li, J.; Zhao, C-Wei.; Zhang, L. 2006: Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs. Yao Xue Xue Bao 41(1): 24-29

Xiao, S-huai.; Wei, G-li.; Lu, R.; Liu, C-xiao.; Wang, F-peng. 2004: Pharmacokinetics of bromotetrandrin (W198) in rats and beagle dogs. Yao Xue Xue Bao 39(4): 301-304

Worrall, S.P.R.; Almond, M.K.; Dhillon, S. 2004: Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron. Clinical Practice 97(3): C83-C89

Warren, K.; Gervais, A.; Aikin, A.; Egorin, M.; Balis, F.M. 2004: Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer ChemoTherapy and Pharmacology 54(3): 206-212

Akramova, D.G.; Ayupova, F.M.; Khakimov, Z.Z. 2005: Pharmacokinetics of cardiogreen in uterine myoma. Uzbekiston Tibbiet Zhurnali 3: 45-47

Petrikkos, G.; Kastanakis, M.; Markogiannakis, A.; Kastanakis, S.; Bastounis, E.; Antonios, P.; Daikos, G.L.; Katsilambros, N. 2006: Pharmacokinetics of cefepime in bile and gall bladder tissue after prophylactic administration in patients with extrahepatic biliary diseases. International Journal of Antimicrobial Agents 27(4): 331-334

Stegemann, M.R.; Sherington, J.; Coati, N.; Brown, S.A.; Blanchflower, S. 2006: Pharmacokinetics of cefovecin in cats. Journal of Veterinary Pharmacology and Therapeutics 29(6): 513-524

Zhu-Yu-Bing; Zou-Jian-Jun; Qian-Wei; Hu-Yun-Fang; Yu-Cui-Xia; Xiao-Da-Wei 2006: Pharmacokinetics of cetirizine through healthy volunteers taking cetirizine and pseudoephedrine sustained-release tablets. Zhongguo Xinyao yu Linchuang Zazhi 25(2): 84-87

Chen, A-Shu.; Taguchi, T.; Okamoto, H.; Danjo, K.; Sakai, K.; Matahira, Y.; Wang, M-Wei.; Miwa, I. 2005: Pharmacokinetics of chitobiose and chitotriose administered intravenously or orally to rats. Biological and Pharmaceutical Bulletin 28(3): 545-548

Huang ZhiYong; Sun MaoYing; Li Sen; Huang GaoLing 2006: Pharmacokinetics of chloramphenicol in carp (Cyprinus carpio L.) after drug administration. Aquaculture Research 37(15): 1540-1545

Xuguang, S.; Yanchuang, L.; Feng, Z.; Shiyun, L.; Xiaotang, Y. 2006: Pharmacokinetics of chlorhexidine gluconate 0.02% in the rabbit cornea. Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 22(4): 227-230

Terlinden, R.; Uragg, H.; Göhler, K.; Kneip, C. 2006: Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. Contraception 74(3): 239-244

Baek, H.W.; Bae, S.K.; Lee, M.G.; Sohn, Y.T. 2006: Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. Journal of Pharmaceutical Sciences 95(11): 2452-2462

Cattel, L.; De Simone, M.; Passera, R.; Verlengo, M.Cristina.; Delprino, L. 2004: Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis. Anticancer Research 24(3b): 2041-2045

Womble, A.Y.; Giguère, S.; Lee, E.A.; Vickroy, T.W. 2006: Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals. American Journal of Veterinary Research 67(10): 1681-1686

Lee, A.K.; Lee, J.H.; Kwon, J.W.; Kim, W.B.; Kim, S.G.; Kim, S.H.; Lee, M.G. 2004: Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharmaceutics and Drug Disposition 25(6): 273-282

Taubert, D.; Kastrati, A.; Harlfinger, S.; Gorchakova, O.; Lazar, A.; von Beckerath, N.; Schömig, A.; Schömig, E. 2004: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thrombosis and Haemostasis 92(2): 311-316

Gustafson, D.L.; Merz, A.L.; Long, M.E. 2005: Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Letters 220(2): 161-169

Weng-Jing-Yan; Hang-Tai-Jun; Zhang-Hong-Wen; Wang-Wei-Qing; Liu-Guang-Yu 2006: Pharmacokinetics of compound famotidine chewing tablets. Zhongguo Xinyao yu Linchuang Zazhi 25(7): 523-526

Kotb, H.I.M.; El-Kady, S.A.; Emara, S.E.S.; Fouad, E.A.; El-Kabsh, M.Y. 2004: Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. British Journal of Anaesthesia 94(1): 95-99

Pradilla, G.; Wang, P.P.; Legnani, F.G.; Frazier, J.L.; Tamargo, R.J. 2004: Pharmacokinetics of controlled-release polymers in the subarachnoid space after subarachnoid hemorrhage in rabbits. Journal of Neurosurgery 101(1): 99-103

Casale, F.; Lupo, F.; Passera, R.; Liddo, G.; Moscato, D.; Mosso, R.; Zara, G.P.; Eandi, M.; Salizzoni, M. 2006: Pharmacokinetics of cyclosporine in recipients of marginal versus standard liver transplants. Pharmacological Research 54(4): 287-292

Akins, R.L.; Haase, M.R.; Levy, E.N. 2006: Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. PharmacoTherapy 26(5): 694-698

Acacio, B.D.; Stanczyk, F.Z.; Mullin, P.; Saadat, P.; Jafarian, N.; Sokol, R.Z. 2004: Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertility and Sterility 81(3): 595-604

Kim, S.Y.; Moon, C.S.; Choi, Y.S.; Lee, S.B. 2004: Pharmacokinetics of dehydroevodiamine following intravenous administration in rats. Korean Journal of Physiology and Pharmacology 8(1): 65-67

Huupponen, R.; Anttila, M.; Rouru, J.; Kanerva, H.; Miettinen, T.; Scheinin, M. 2004: Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 42(8): 449-455

Osterberg, O.; Savic, R.M.; Karlsson, M.O.; Simonsson, U.S.H.; Nørgaard, J.P.; Walle, J.V.; Agersø, H. 2006: Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. Journal of Clinical Pharmacology 46(10): 1204-1211

Valles, J.; Artigas, R.; Mas, M.; Crea, A.; Muller, F.; Paredes, I.; Capriati, A. 2006: Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. Methods and Findings in Experimental and Clinical Pharmacology 28(Suppl): 21-28

Fennell, T.R.; Krol, W.L.; Sumner, S.C.J.; Snyder, R.W. 2004: Pharmacokinetics of dibutylphthalate in pregnant rats. Toxicological Sciences: An Official Journal of the Society of Toxicology 82(2): 407-418

Pejcic, Z.; Pokrajac, M.; Jezdimirovic, M. 2006: Pharmacokinetics of diclofenac in pigs after intramuscular administration of a single dose. Acta Veterinaria Beograd 56(4): 323-331

Kim, Y.C.; Oh, E.Y.; Kim, S.H.; Lee, M.G. 2006: Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. Biopharmaceutics and Drug Disposition 27(2): 85-92

L.Y.ng; Xie Dong Ling; Zhou Zheng; Wang Gao Feng; Gao Yuan Xun 2004: Pharmacokinetics of diclofenac sodium delayed-action preparation. Zhongguo Xinyao yu Linchuang Zazhi 23(6): 342-345

Kovacs, A.; Cowles, M.Kathryn.; Britto, P.; Capparelli, E.; Fowler, M.Glenn.; Moye, J.; McIntosh, K.; Rathore, M.H.; Pitt, J.; Husson, R.N. 2005: Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. Pediatric Infectious Disease Journal 24(6): 503-509

McGready, R.; Stepniewska, K.; Ward, S.A.; Cho, T.; Gilveray, G.; Looareesuwan, S.; White, N.J.; Nosten, F. 2006: Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology 62(5): 367-371

Sheng Rong, G.; Lan Jun, W.; Xiao Min, W.; Xiao Yang, L. 2004: Pharmacokinetics of domestic and imported meloxicam tablets following a single dose in healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 23(4): 195-198

Liu, D.; Wang, P-cheng.; Qi, X-rong.; Zou, Q.; Zou, Y-hua.; Hong, H. 2006: Pharmacokinetics of doxorubicin alginate microspheres and evaluation of its hepatic arterial embolization in vivo. Yao Xue Xue Bao 41(8): 778-783

Leen, C.; Wat, C.; Nieforth, K. 2004: Pharmacokinetics of enfuvirtide in a patient with impaired renal function. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 39(11): E119-E121

Stocker, H.; Kloft, C.; Plock, N.; Breske, A.; Kruse, G.; Herzmann, C.; Schulbin, H.; Kreckel, P.; Weber, C.; Goebel, F.; Roeling, J.; Staszewski, S.; Plettenberg, A.; Moecklinghoff, C.; Arastéh, K.; Kurowski, M. 2006: Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrobial Agents and ChemoTherapy 50(2): 667-673

Kim, M.-S.; Lim, J.-H.; Park, B.-K.; Hwang, Y.-H.; Yun, H.-I. 2006: Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). Journal of Veterinary Pharmacology and Therapeutics 29(5): 397-402

Ravis, W.R.; Reid, S.; Sica, D.A.; Tolbert, D.S. 2005: Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. Journal of Clinical Pharmacology 45(7): 810-821

Mistry, G.C.; Majumdar, A.K.; Swan, S.; Sica, D.; Fisher, A.; Xu, Y.; Hesney, M.; Xi, L.; Wagner, J.A.; Deutsch, P.J. 2006: Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. Journal of Clinical Pharmacology 46(10): 1128-1138

Dey, S.; Gunda, S.; Mitra, A.K. 2004: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. Journal of Pharmacology and Experimental Therapeutics 311(1): 246-255

Dey, S.; Gunda, S.; Mitra, A.K. 2005: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: Role of P-glycoprotein as a barrier to in vivo ocular drug absorption (vol 311, pg 246, 2004). Journal of Pharmacology and Experimental Therapeutics 314(1): 483

Niazi, M.; Ahlbom, H.; Bondarov, P.; Karlsson, A.H.; Hassan-Alin, M.; Rydholm, H.; Röhss, K. 2005: Pharmacokinetics of esomeprazole following varying intravenous administration rates. Basic and Clinical Pharmacology and Toxicology 97(6): 351-354

Järvinen, A.; Kainulainen, P.; Nissilä, M.; Nikkanen, H.; Kela, M. 2004: Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. Maturitas 47(3): 209-217

Djaldetti, R.; Giladi, N.; Hassin-Baer, S.; Shabtai, H.; Melamed, E. 2003: Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clinical Neuropharmacology 26(6): 322-326

Schroeder, P.E.; Hofland, K.Francis.; Jensen, P.Buhl.; Sehested, M.; Langer, S.W.; Hasinoff, B.B. 2004: Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology 53(1): 91-93

Agrawal, N.G.B.; Matthews, C.Z.; Mazenko, R.S.; Kline, W.F.; Woolf, E.J.; Porras, A.G.; Geer, L.A.; Wong, P.H.; Cho, M.; Cote, J.; Marbury, T.C.; Moncrief, J.W.; Alcorn, H.; Swan, S.; Sack, M.R.; Robson, R.A.; Petty, K.J.; Schwartz, J.I.; Gottesdiener, K.M. 2004: Pharmacokinetics of etoricoxib in patients with renal impairment. Journal of Clinical Pharmacology 44(1): 48-58

Vásquez, L.; Scorza Dagert, J.é V.; Scorza, J.é V.; Vicuña-Fernández, N.; de Peña, Y.P.; López, S.; Bendezú, H.; Rojas, E.; Vásquez, L.; Pérez, B.én. 2006: Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers. Current Therapeutic Research 67(3): 193-203

Bafeltowska, J.J.; Buszman, E. 2005: Pharmacokinetics of fluconazole in the cerebrospinal fluid of children with hydrocephalus. ChemoTherapy 51(6): 370-376

Ferguson, J.M.; Hill, H. 2006: Pharmacokinetics of fluoxetine in elderly men and women. Gerontology 52(1): 45-50

Sobue, S.; Tan, K.; Layton, G.; Eve, M.; Sanderson, J.B. 2004: Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. British Journal of Clinical Pharmacology 58(1): 20-25

Ding-Li; Yang-Jin; Li-Rong-Shan; Zhou-Mei; Shen-Jian-Ping; Zhang-Yin-Di 2005: Pharmacokinetics of fudosteine in healthy volunteers. Yaoxue Xuebao 40(10): 945-949

Ohman, I.; Vitols, S.; Tomson, T.ör. 2005: Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?. Epilepsia 46(10): 1621-1624

Tallian, K.B.; Nahata, M.C.; Lo, W.; Tsao, C-Y. 2004: Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. Journal of Clinical Pharmacy and Therapeutics 29(6): 511-515

Asano-Mori, Y.; Kanda, Y.; Oshima, K.; Watanabe, T.; Shoda, E.; Motokura, T.; Kurokawa, M.; Chiba, S. 2006: Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. Journal of Antimicrobial ChemoTherapy 57(5): 1004-1007

Capparelli, E.V.; Reed, M.D.; Bradley, J.S.; Kearns, G.L.; Jacobs, R.F.; Damle, B.D.; Blumer, J.L.; Grasela, D.M. 2005: Pharmacokinetics of gatifloxacin in infants and children. Antimicrobial Agents and ChemoTherapy 49(3): 1106-1112

Bu-Xiu-Yun; Zhang-Guo-Liang 2006: Pharmacokinetics of gatifloxacin mesylate and gatifloxacin in rats in vivo. Zhongguo Yaolixue Tongbao 22(6): 751-754

Li-Hong-Li; Wen-Ai-Dong; Luo-Xiao-Xing; Wu-Yin; Zhao-Lei; Li-Wei 2004: Pharmacokinetics of gatifloxacin mesylate tablets in healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 23(9): 586-588

McKillop, D.; Partridge, E.A.; Hutchison, M.; Rhead, S.A.; Parry, A.C.; Bardsley, J.; Woodman, H.M.; Swaisland, H.C. 2004: Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 34(10): 901-915

Czejka, M.; Ostermann, E.; Muric, L.; Heinz, D.; Schueller, J. 2005: Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. Onkologie 28(6-7): 318-322

Buckwalter, M.; Dowell, J.A.; Korth-Bradley, J.; Gorovits, B.; Mayer, P.R. 2004: Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. Journal of Clinical Pharmacology 44(8): 873-880

Batchelor, D.C.; Lin, H.; Wen, J-Y.; Keven, C.; Van Zijl, P.L.; Breier, B.H.; Gluckman, P.D.; Thomas, G.B. 2003: Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Analytical Biochemistry 323(2): 156-163

Bakaevea, Z.V.; Samonina, G.E.; Andreeva, L.A.; Zolotarev, I.A.; Kozik, V.S.; Ashmarin, I.P.; Miasoedov, N.F. 2004: Pharmacokinetics of glyprolines (PGP) upon intragastric administration. Eksperimental'naia i Klinicheskaia Farmakologiia 67(4): 57-60

Nava-Ocampo, A.A.; Pastrak, A.; Cruz, T.; Koren, G. 2005: Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. Clinical and Experimental Pharmacology and Physiology 32(1-2): 13-18

Girardin, F.ço.; Rentsch, K.M.; Schwab, M.-A.é; Maggiorini, M.; Pauli-Magnus, C.; Kullak-Ublick, G.A.; Meier, P.J.; Fattinger, K. 2003: Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clinical Pharmacology and Therapeutics 74(4): 341-352

Mcaleer, S.D.; Mills, R.J.; Polack, T.; Hussain, T.; Rolan, P.E.; Gibbs, A.D.; Mullins, F.G.P.; Hussein, Z. 2003: Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. Drug and Alcohol Dependence 72(1): 75-83

Chemysheva, G.A.; Smol'yakova, V.I.; Plotnikov, M.B.; Cherkashina, I.V. 2006: Pharmacokinetics of high-molecular-weight poly(ethylene oxide). Khimiko Farmatsevticheskii Zhurnal 40(9): 7-8

Liu, Y-ju.; Shang, J-chuan.; Gao, L-jia.; He, Y-na.; Zhou, L-ping.; Mu, Z-de. 2006: Pharmacokinetics of hylotelephin in Beagle dogs. Yao Xue Xue Bao 41(7): 680-683

Sörgel, F.; Fuhr, U.; Minic, M.; Siegmund, M.; Maares, J.; Jetter, A.; Kinzig-Schippers, M.; Tomalik-Scharte, D.; Szymanski, J.; Goeser, T.; Toex, U.; Scheidel, B.; Lehmacher, W. 2005: Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. International Journal of Clinical Pharmacology and Therapeutics 43(3): 140-149

Pappas, P.; Karavasilis, V.; Briasoulis, E.; Pavlidis, N.; Marselos, M. 2005: Pharmacokinetics of imatinib mesylate in end stage renal disease. a case study. Cancer ChemoTherapy and Pharmacology 56(4): 358-360

Jaruratanasirikul, S.; Raungsri, N.; Punyo, J.; Sriwiriyajan, S. 2005: Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. Journal of Antimicrobial ChemoTherapy 56(6): 1163-1165

Dirks, N.L.; Huth, B.; Yates, C.R.; Meibohm, B. 2004: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. International Journal of Clinical Pharmacology and Therapeutics 42(12): 701-718

DiCenzo, R.; Forrest, A.; Fischl, M.A.; Collier, A.; Feinberg, J.; Ribaudo, H.; DiFrancecso, R.; Morse, G.D. 2004: Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrobial Agents and ChemoTherapy 48(3): 918-923

Rhame, F.S.; Rawlins, S.L.; Petruschke, R.A.; Erb, T.A.; Winchell, G.A.; Wilson, H.M.; Edelman, J.M.; Abramson, M.A. 2004: Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrobial Agents and ChemoTherapy 48(11): 4200-4208

Lee, L.S.; Panchalingam, A.; Yap, M.C.; Paton, N.I. 2004: Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus. Antimicrobial Agents and ChemoTherapy 48(11): 4476-4478

Bergshoeff, A.S.; Fraaij, P.L.A.; van Rossum, A.M.C.; Verweel, G.; Wynne, L.H.; Winchell, G.A.; Leavitt, R.Y.; Nguyen, B-Y.T.; de Groot, R.; Burger, D.M. 2004: Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. Antimicrobial Agents and Chemotherapy 48(5): 1904-1907

Aarnoutse, R.E.; Brinkman, K.; Benetucci, J.; Begovac, J.; Stek, M.; Burger, D.M. 2004: Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. Aids 18(3): 565-567

Boyd, M.A.; Aarnoutse, R.E.; Ruxrungtham, K.; Stek, M.; van Heeswijk, R.P.G.; Lange, J.M.A.; Cooper, D.A.; Phanuphak, P.; Burger, D.M. 2003: Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes 34(2): 134-139

Li, D.-Mei; Lu, W.-Liang; Wang, X.-Qing; Wang, J.-Cheng; Zhang, H.; Zhang, R.-Juan; Wang, G.-Lin; Zhang, X.; Zhang, Q. 2005: Pharmacokinetics of indomethacin, a metabolite of acemetacin, following a single dose and multiple doses administered as acemetacin sustained-release tablets in healthy male volunteers. Journal of Health Science 51(3): 308-316

Brosnan, R.J.; Pypendop, B.H.; Barter, L.S.; Hawkins, M.G. 2006: Pharmacokinetics of inhaled anesthetics in green iguanas (Iguana iguana). American Journal of Veterinary Research 67(10): 1670-1674

Ratjen, F.; Rietschel, E.; Kasel, D.; Schwiertz, R.; Starke, K.; Beier, H.; van Koningsbruggen, S.; Grasemann, H. 2006: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial ChemoTherapy 57(2): 306-311

Elwell, R.J.; Manley, H.J.; Frye, R.F.; Bailie, G.R. 2005: Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. International Journal of Artificial Organs 28(8): 808-816

Krupp, J.L.; Bernards, C.M. 2004: Pharmacokinetics of intrathecal oligodeoxynucleotides. Anesthesiology 100(2): 315-322

Brown, M.; Bjorksten, A.; Medved, I.; McKenna, M. 2004: Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. European Journal of Clinical Pharmacology 60(10): 717-723

Koleba, T.; Ensom, M.H.H. 2006: Pharmacokinetics of intravenous immunoglobulin: a systematic review. PharmacoTherapy 26(6): 813-827

Würthwein, G.; Koling, S.; Reich, A.; Hempel, G.; Schulze-Westhoff, P.; Pinheiro, P.V.; Boos, J. 2005: Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. European Journal of Clinical Pharmacology 60(12): 883-888

Pullen, J.; Stolk, L.M.L.; Degraeuwe, P.L.J.; van Tiel, F.H.; Neef, C.; Zimmermann, L.J.I. 2006: Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. Therapeutic Drug Monitoring 28(5): 654-661

Türck, D.; Weber, W.; Sigmund, R.; Budde, K.; Neumayer, H.-H.; Fritsche, L.; Rominger, K.-L.; Feifel, U.; Slowinski, T. 2004: Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. Journal of Clinical Pharmacology 44(2): 163-172

Jacobs, R.F.; Maples, H.D.; Aranda, J.V.; Espinoza, G.M.; Knirsch, C.; Chandra, R.; Fisher, J.M.; Kearns, G.L. 2005: Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatric Infectious Disease Journal 24(1): 34-39

Overholser, B.R.; Kays, M.B.; Lagvankar, S.; Goldman, M.; Mueller, B.A.; Sowinski, K.M. 2005: Pharmacokinetics of intravenously administered levofloxacin in men and women. PharmacoTherapy 25(10): 1310-1318

Wang, J.-C.; Liu, X.-Y.; Lu, W.-L.; Chang, A.; Zhang, Q.; Goh, B.-C.; Lee, H.-S. 2006: Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 62(1): 44-51

Schmidt Laugesen, C.; Steffansen, B.; Scherfig, E.; la Cour, M. 2005: Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. Acta Ophthalmologica Scandinavica 83(2): 184-190

Tzeng, J.-I.; Su, W.-L.; Chu, K.-S.; Cheng, K.-I.; Chu, C.-C.; Shieh, J.-P.; Wang, J.-J. 2005: Pharmacokinetics of ketorolac pentyl ester, a novel ester derivative of ketorolac, in rabbits. Kaohsiung Journal of Medical Sciences 21(8): 365-370

Chen, J.; Ping, Q.; Guo, J.; Chu, X.; Song, M. 2006: Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats. Biopharmaceutics and Drug Disposition 27(2): 53-59

Hu, Y-Rong.; Qiao, H-Ling.; Kan, Q-Cheng. 2004: Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacologica Sinica 25(8): 986-990

Brockmöller, J.ür.; Thomsen, T.; Wittstock, M.; Coupez, R.é; Lochs, H.; Roots, I. 2005: Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clinical Pharmacology and Therapeutics 77(6): 529-541

Chalkiadis, G.A.; Eyres, R.L.; Cranswick, N.; Taylor, R.H.; Austin, S. 2004: Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. British Journal of Anaesthesia 92(2): 218-222

Chalkiadis, G.A.; Anderson, B.J.; Tay, M.; Bjorksten, A.; Kelly, J.J. 2005: Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. British Journal of Anaesthesia 95(4): 524-529

Antila, S.; Pesonen, U.; Lehtonen, L.; Tapanainen, P.; Nikkanen, H.; Vaahtera, K.; Scheinin, H. 2004: Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 23(3): 213-222

Vogelsinger, H.; Joannidis, M.; Kountchev, J.; Bellmann-Weiler, R.; Wiedermann, C.J.; Bellmann, R. 2006: Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis. Artificial Organs 30(2): 118-121

Mross, K.; Niemann, B.; Massing, U.; Drevs, J.; Unger, C.; Bhamra, R.; Swenson, C.E. 2004: Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer ChemoTherapy and Pharmacology 54(6): 514-524

Muindi, J.R.; Potter, D.M.; Peng, Y.; Johnson, C.S.; Trump, D.L. 2005: Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer ChemoTherapy and Pharmacology 56(5): 492-496

Turncliff, R.Z.; Dunbar, J.L.; Dong, Q.; Silverman, B.L.; Ehrich, E.W.; Dilzer, S.C.; Lasseter, K.C. 2005: Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. Journal of Clinical Pharmacology 45(11): 1259-1267

Oki, T.; Usami, Y.; Nakai, M.; Sagisaka, M.; Ito, H.; Nagaoka, K.; Mamiya, N.; Yamanaka, K.; Utsumi, M.; Kaneda, T. 2004: Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers. Biological and Pharmaceutical Bulletin 27(2): 261-265

Peng, J.Z.; Pulido, F.; Causemaker, S.J.K.; Li, J.; Lorenzo, A.; Cepeda, C.ón.; García Cabanillas, J.A.; DaSilva, B.; Brun, S.C.; Arribas, J.é 2006: Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. Journal of Clinical Pharmacology 46(3): 265-274

Gao-Na; Zhang-Li-Rong; Wang-Xiu-Li; Jia-Lin-Jing; Guo-Yu-Zhong; Tian-Xin; Qiao-Hai-Ling 2005: Pharmacokinetics of lorazepam injection in Chinese healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 24(10): 785-788

Joerger, M.; Huitema, A.D.R.; Meenhorst, P.L.; Schellens, J.H.M.; Beijnen, J.H. 2005: Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer ChemoTherapy and Pharmacology 55(5): 488-496

Feuchtl, A.; Bagli, M.; Stephan, R.; Frahnert, C.; Kölsch, H.; Kühn, K.U.; Rao, M.L. 2004: Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 37(4): 180-188

Yang, Z-fu.; Zhou, S-yuan.; Yang, T-hong.; Mei, Q-bing. 2004: Pharmacokinetics of m-nifedipine in Beagle dogs. Yao Xue Xue Bao 39(8): 609-612

Shen-Jin-Fang; Sun-Li; Li-Duan 2005: Pharmacokinetics of magnesium isoglycyrrhizinate after a single and multiple intravenous dose in healthy volunteers. Zhongguo Xinyao yu Linchuang Zazhi 24(2): 85-89

Schneider, M.; Vallé, M.; Woehrlé, F.; Boisramé, B. 2004: Pharmacokinetics of marbofloxacin in lactating cows after repeated intramuscular administrations and pharmacodynamics against mastitis isolated strains. Journal of Dairy Science 87(1): 202-211

Bohlooli, S.; Keyhanfar, F.; Mahmoudian, M. 2004: Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. Biopharmaceutics and Drug Disposition 25(4): 187-191

Burgos-Vargas, R.én.; Foeldvari, I.; Thon, A.; Linke, R.; Tuerck, D. 2004: Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. Journal of Clinical Pharmacology 44(8): 866-872

Lin-Cai; Liu-Song-Qing; Dai-Qing; He-Jun-Ving 2004: Pharmacokinetics of meropenem in the patients with burn injury. Zhongguo Kangshengsu Zazhi 29(2): 118-123

Stagni, G.; Shukla, C. 2003: Pharmacokinetics of methotrexate in rabbit skin and plasma after iv-bolus and iontophoretic administrations. Journal of Controlled Release: Official Journal of the Controlled Release Society 93(3): 283-292

Luo-Hong-Jun; Li-Hui; Luo-Wen-Hong 2006: Pharmacokinetics of methylamine and its metabolite formaldehyde in animals. Zhongguo Yaolixue Yu Dulixue Zazhi 20(2): 120-124

Eap, C.B.; Buclin, T.; Hustert, E.; Bleiber, G.; Golay, K.P.; Aubert, A.-C.; Baumann, P.; Telenti, A.; Kerb, R. 2004: Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. European Journal of Clinical Pharmacology 60(4): 231-236

Nitsun, M.; Szokol, J.W.; Saleh, H.J.; Murphy, G.S.; Vender, J.S.; Luong, L.; Raikoff, K.; Avram, M.J. 2006: Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. Clinical Pharmacology and Therapeutics 79(6): 549-557

Wang-Hua-Li; Huang-Wen-Xiang; Sheng-Jia-Qi 2006: Pharmacokinetics of minocycline hydrochloride for injection in healthy human. Zhongguo Kangshengsu Zazhi 31(1): 33-35

Cerretani, D.; Nencini, C.; Urso, R.; Giorgi, G.; Marrelli, D.; De Stefano, A.; Pinto, E.; Cioppa, T.; Nastri, G.; Roviello, F. 2005: Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. Journal of ChemoTherapy 17(6): 668-673

Chin, C.M.; Gutierrez, M.; Still, J.Gordon.; Kosutic, G. 2004: Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy 24(8): 994-1001

Kremer, J.J.; Williams, C.C.; Parkinson, H.D.; Borghoff, S.J. 2005: Pharmacokinetics of monobutylphthalate, the active metabolite of di-n-butylphthalate, in pregnant rats. Toxicology Letters 159(2): 144-153

Migoya, E.; Kearns, G.L.; Hartford, A.; Zhao, J.; van Adelsberg, J.; Tozzi, C.A.; Knorr, B.; Deutsch, P. 2004: Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. Journal of Clinical Pharmacology 44(5): 487-494

Fuhrmann, V.; Schenk, P.; Jaeger, W.; Ahmed, S.; Thalhammer, F. 2004: Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. Journal of Antimicrobial ChemoTherapy 54(4): 780-784

González-Roncero, F.M.; Gentil, M.A.; Brunet, M.; Algarra, G.; Pereira, P.; Cabello, V.; Peralvo, M. 2006: Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplantation Proceedings 37(9): 3749-3751

Akhlaghi, F.; Patel, C.G.; Zuniga, X.Patricia.; Halilovic, J.; Preis, I.S.; Gohh, R.Y. 2006: Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Therapeutic Drug Monitoring 28(1): 95-101

El Haggan, W.; Ficheux, M.; Debruyne, D.; Rognant, N.; Lobbedez, T.; Allard, C.; Coquerel, A.; Ryckelynck, J.P.; Hurault de Ligny, B. 2005: Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. Transplantation Proceedings 37(2): 864-866

Julasareekul, W.; Eiam-Ong, S.; Bejraputra, O.; Seublinvong, T. 2003: Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil. Journal of the Medical Association of Thailand 86(8): 766-771

Von Eye Corleta, H.; Capp, E.; Ferreira, M.B.C. 2004: Pharmacokinetics of natural progesterone vaginal suppository. Gynecologic and Obstetric Investigation 58(2): 105-108

Smith, P.F.; Robbins, G.K.; Shafer, R.W.; Wu, H.; Yu, S.; Hirsch, M.S.; Merigan, T.C.; Park, J.-G.; Forrest, A.; Fischl, M.A.; Morse, G.D. 2005: Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrobial Agents and ChemoTherapy 49(8): 3558-3561

Villani, P.; Floridia, M.; Pirillo, M.F.; Cusato, M.; Tamburrini, E.; Cavaliere, A.F.; Guaraldi, G.; Vanzini, C.; Molinari, A.; degli Antoni, A.; Regazzi, M. 2006: Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. British Journal of Clinical Pharmacology 62(3): 309-315

Damle, B.; Hewlett, D.; Hsyu, P.-H.; Becker, M.; Petersen, A. 2006: Pharmacokinetics of nelfinavir in subjects with hepatic impairment. Journal of Clinical Pharmacology 46(11): 1241-1249

Chokephaibulkit, K.; Plipat, N.; Cressey, T.R.; Frederix, K.; Phongsamart, W.; Capparelli, E.; Kolladarungkri, T.; Vanprapar, N. 2005: Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. Aids 19(14): 1495-1499

Anand, B.S.; Katragadda, S.; Mitra, A.K. 2004: Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. Journal of Pharmacology and Experimental Therapeutics 311(2): 659-667

Chulavatnatol, S.; Chindavijak, B.; Chierakul, N.; Klomsawat, D. 2003: Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. Journal of the Medical Association of Thailand 86(8): 781-788

Markowitz, J.S.; DeVane, C.Lindsay.; Malcolm, R.J.; Gefroh, H.A.; Wang, J-Sheng.; Zhu, H-Jie.; Donovan, J.L. 2006: Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. Journal of Clinical Pharmacology 46(2): 164-171

Kreutz, R.; Bolbrinker, J.; Huber, M. 2006: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clinical Drug Investigation 26(1): 29-34

Bae, S.K.; Lee, S.J.; Kim, J.W.; Kim, Y.H.; Kim, S.G.; Lee, M.G. 2005: Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours. Biopharmaceutics and Drug Disposition 26(2): 77-83

Bae, S.K.; Kang, H.E.; Kang, M.K.; Kim, J.W.; Kim, T.; Lee, M.G. 2006: Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats. Journal of Pharmaceutical Sciences 95(5): 998-1005

Bae, S.K.; Kim, J.Y.; Yang, S.H.; Kim, J.W.; Kim, T.; Lee, M.G. 2006: Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. Life Sciences 78(20): 2287-2294

Marier, J.-F.; Dubuc, M.-C.; Drouin, E.; Alvarez, F.; Ducharme, M.P.; Brazier, J.-L. 2004: Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. Therapeutic Drug Monitoring 26(1): 3-8

Kumar, R.; Chawla, Y.K.; Garg, S.K.; Dixit, R.K.; Satapathy, S.K.; Dhiman, R.K.; Bhargava, V.K. 2003: Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. Methods and Findings in Experimental and Clinical Pharmacology 25(8): 625-630

la Porte, C.J.L.; Schippers, E.F.; van der Ende, M.E.; Koopmans, P.P.; Blok, W.L.; Kauffmann, R.H.; Kroon, F.P.; Burger, D.M. 2005: Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications. Aids 19(10): 1105-1107

Kwak, H.H.; Kim, J.O.; Chung, H.K.; Choi, S.M.; Kim, J.H.; Kwon, J.W.; Yoo, M.; Lee, J.H.; Lee, M.G. 2006: Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. Biopharmaceutics and Drug Disposition 27(3): 141-145

Li-Wen-Jun; Peng-Xiao-Ying; Ma-Zhang-Yin; Zheng-Yong-Xing 2004: Pharmacokinetics of oral antitumor drug satraplatin in rats. Zhongguo Xinyao yu Linchuang Zazhi 23(8): 528-530

Litjens, N.H.R.; Burggraaf, J.; van Strijen, E.; van Gulpen, C.; Mattie, H.; Schoemaker, R.C.; van Dissel, J.T.; Thio, H.Bing.; Nibbering, P.H. 2004: Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology 58(4): 429-432

Fetterly, G.J.; Ong, C.M.; Bhavnani, S.M.; Loutit, J.S.; Porter, S.B.; Morello, L.G.; Ambrose, P.G.; Nicolau, D.P. 2004: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrobial Agents and ChemoTherapy 49(1): 148-152

Paccaly, A.; Frick, A.; Rohatagi, S.; Liu, J.; Shukla, U.; Rosenburg, R.; Hinder, M.; Jensen, B.K. 2006: Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. Journal of Clinical Pharmacology 46(1): 37-44

Merkel, U.; Farker, K.; Wedding, U.; Roskos, M.; Hippius, M.; Höffken, K.; Hoffmann, A. 2006: Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation. International Journal of Clinical Pharmacology and Therapeutics 44(3): 128-134